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Syntaxin 6- and microtubule- mediated intracellular trafficking contributes to
Golgi and nuclear translocation of EGFR
Publication No. _____________
Yi Du
Supervisory Professor: Mien-Chie Hung, Ph.D.
Receptor-mediated endocytosis is well known for its degradation and recycling
trafficking. Recent evidence shows that these cell surface receptors translocate from
cell surface to different cellular compartments, including the Golgi, mitochondria,
endoplasmic reticulum (ER), and the nucleus to regulate physiological and
pathological functions. Although some trafficking mechanisms have been resolved,
the mechanism of intracellular trafficking from cell surface to the Golgi is not yet
completed understood. Here we report a mechanism of Golgi translocation of EGFR
in which EGF-induced EGFR travels to the Golgi via microtubule (MT)-dependent
movement by interacting with dynein and fuses with the Golgi through syntaxin 6
(Syn6)-mediated membrane fusion. We also demonstrate that the Golgi translocation
of EGFR is necessary for its consequent nuclear translocation and transcriptional
activity. Interestingly, foreign protein such as bacterial cholera toxin, which is known
to activate its pathological function through the Golgi/ER retrograde pathway, also
utilizes the MT/Syn6 pathway. Thus, the MT, and syntaxin 6 mediated trafficking
pathway from cell surface to the Golgi and ER defines a comprehensive retrograde
trafficking route for both cellular and foreign molecules to travel from cell surface to
the Golgi and the nucleus.
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Chapter One
Introduction
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1.1 Receptor tyrosine kinases and ErbB family
Receptor tyrosine kinases (RTKs) are a big family of cell surface
transmembrane proteins which catalyze the transfer of the γ-phosphate of adenosine5'-triphosphate (ATP) to hydroxyl groups of tyrosine on target proteins. RTKs play
important physiological and pathological roles in response to their ligand’s
stimulation (Lemmon and Schlessinger, 2010; Yarden and Shilo, 2007). Ligand
binding induces the dimerization of receptor and initiates the tyrosine kinases activity
through the phosphorylation of tyrosine residues at their C-terminal domain (Sorkin
and Goh, 2008). However, ligand is not always required for the tyrosine activity. In
some cases, even in the absence of ligands, dimerization or oligomerization of
receptors still occurs and turns on the tyrosine activity (Noordeen et al., 2006;
Schlessinger et al., 2002; Weiss et al., 1997). Based on the structural and functional
domain, about 20 subfamilies of RTKs are identified, such as erythroblastic leukemia
viral oncogene homolog (ErbB) receptors, insulin receptor (InsR), platelet derived
growth factor receptor (PDGFR), vascular endothelial growth factor

receptor

(VEGFR), and fibroblast growth factor receptor (FGFR) (Lemmon and Schlessinger,
2010).
ErbB proteins are a family which consists of ErbB1 (epidermal growth factor
receptor (EGFR)), ErbB2 (human epidermal growth factor receptor 2 (HER2)),
ErbB3, and ErbB4. Excessive ErbB signaling is associated with the development of a
wide variety of human tumor (Hynes and Lane, 2005; Hynes and MacDonald, 2009).
For example, aberrant expression or amplification of ErbB-1 and ErbB-2 are found in
many human cancers, and their signaling may be critical in the development and
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malignancy of these tumors. EGFR is the first ErbB family protein discovered as a
receptor tyrosine kinase (Carpenter, 2000; Haigler et al., 1978). Epidermal growth
factor (EGF), transforming growth factor alpha (TGF-α) or heparin-binding EGF-like
growth factor (HB-EGF) stimulates the dimerization of EGFR which causes the
autophosphorylation of several tyrosine (Y) residues at carboxy-terminal domain
including Y992, Y1045, Y1068, Y1086, Y1148, and Y1173 (Figure 1-1) (Bishayee et
al., 1999a, b; Hunter, 1984; Lombardo et al., 1995; Reynolds et al., 1981).

Figure1-1

Figure 1-1: Tyrosine phosphorylation sites of EGFR. Downstream molecules bind
to specific phosphorylated tyrosines at C-terminal domain which are involved in
signaling transduction and intracellular trafficking.
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These phosphorylated tyrosines provide docking sites for downstream
signaling molecules such as Src homolog (SH) domain to transduce signal.
Meanwhile, active EGFR also internalizes into the cytoplasm as endocytic vesicles
for lysosome regulated degradation or recycles to the cell surface to keep signal
transduction under certain conditions (Carpenter and Cohen, 1976; Sorkin and Goh,
2008).

1.2 Endosomal trafficking of EGFR
1.2.1 Traditional endocytosis, degradation, and recycling of EGFR
Receptor mediated endocytosis is considered as a major down-regulation of
EGFR signaling (Figure 1-2) (Beguinot et al., 1984; Brown et al., 1983). Ligands
induced dimerization has been thought as an initial step for signaling transduction via
autophosphorylation of several tyrosine residues at C-terminal domain (Opresko et al.,
1995). These phosphorylated tyrosines also turn on receptor mediated endocytosis,
called clathrin mediated endocytosis (CME) (Figure 1-3), through series of proteinprotein interaction (Sorkina et al., 1999). In CME, clathrin-coated pits are first
constructed by recognition of the sorting signal (Y954xxθ) localized on EGFR by
adaptor protein 2 (AP2) (Jones et al., 2002; Takei and Haucke, 2001). AP2 also has a
binding domain to interact with phosphatidylinositol bisphosphate (PIP2) which
concentrates on the plasma membrane (Robinson, 2004). Then clathrin is recruited to
the plasma membrane via binding to a subunit of AP2 (Huang et al., 2001; Sorkin,
2004). When clusters of clathrin protein accumulate around EGFR, these proteinprotein interactions force plasma membrane to endocytose. The clathrin-coated
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vesicles then release receptor cargo from parental plasma membrane via
internalization (Robinson, 2004).
Figure 1-2

Figure 1-2: Endocytic trafficking of EGFR in response to the ligand’s stimulation.
Ligand induced dimerization of EGFR and internalization. Internalized EGFR transport
from early endosome, late endosome to lysosome for degradation.
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Figure 1-3

Figure 1-3: Comparison of endocytic trafficking mediated by clathrin, caveolin,
and lipid rafts. Receptor-mediated endocytosis is mediated by clathrin from transport
vesicels and early endosome to the lysosome in order to terminate signaling
transduction. Caveolin-mediated caveolae is another endocytosis of cell surface
receptor. Lipid rafts are also involved in the endocytosis and cooperated with caveolin
under certain conditions.
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EGF-induced degradation of EGFR is a well studied process to terminate
EGFR signaling transduction (Wiley and Burke, 2001). After endocytosis, EGFR
transports to the lysosome where it is degradated through the endosomal trafficking
including early endosome and late endosome. The pH value of endosomal
compartments have been shown to continuously decrease to pH5.0 for degradation
process (Yamashiro and Maxfield, 1984; Yamashiro et al., 1984). In cells with
moderate expression of EGFR, the turnover of t1/2 is about 6 hours. However in cells
with overexpression of EGFR such as A431, the turnover time t1/2 is about 24 hours
(Sorkin and Goh, 2008).
Ubiquitylation on lysine residues of EGFR during endocytic traffic is another
biological event to down-regulate EGFR signaling pathway (Levkowitz et al., 1998).
Ubiquitylation is a protein post-transcriptional modification with ubiquitin, a 76amino acid molecule, to the ε-amino group of lysine in target proteins. There are two
major ubiquitylations categorized by K48 linked and K63 linked ubiquitin. K48
linked ubiquitylation is thought to mediate proteasomal degradation, and K63 linked
ubiquitylation is related to the signal transduction and vesicles trafficking (Hershko
and Ciechanover, 1998; Hershko et al., 1983). Cbl (Casitas b-lineage lymphoma) is a
critical E3 ligase that has been reported to form a complex with EGFR via
phosphrylated tyrosine 1045 (Galisteo et al., 1995; Langdon, 1995). Cbl-mediated
ubiquitylation of EGFR is also related to its lysosomal-protesomal degradation
(Galcheva-Gargova et al., 1995; Levkowitz et al., 1999).
Endocytosis recycling is an opposite biological process against endosomal
degradation of EGFR to maintain its signaling transduction (Maxfield and McGraw,
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2004). Once EGFR travels into the cytoplasm via the internalization in response to
ligands’ stimulation, EGFR recycles back to the cell surface to keep the signaling
transduction (Masui et al., 1993; Sorkin et al., 1989). Neu differentiation factor
(NDF/neuregulin) and TGF-α are ligands which have potential to cause EGFR
recycling after endocytosis (Waterman et al., 1998).

1.2.2 Caveolin and lipid rafts regulate endocytosis of EGFR
Caveolin is another protein that regulates endocytosis of EGFR through
ligand-independent pathway (Abulrob et al., 2004; Couet et al., 1997; Mineo et al.,
1996) (Figure 1-3). Different from the ligand induced endocytosis which transports
EGFR to the lysosomal to terminate signaling, caveolin-related endocytosis is thought
to prolong signal transduction of EGFR (Khan et al., 2006; Kim and Bertics, 2002).
Lipid rafts is an additional functional microdomain on the plasma membrane
containing cholesterol, sphingolipid, and gangliosides (Simons and Toomre, 2000). In
lipid raft-mediated endocytosis, lipid raft usually cooperates with caveolin to regulate
endocytosis and signaling transduction. Lipid raft-mediated endocytosis is also
involved in the EGFR signaling in response to virus infection (Eierhoff et al., 2010).
Although lipid rafts usually inhibit ligand induced signaling activation, it enhances
ligand-independent kinase activity of EGFR (Chen and Resh, 2002; Peres et al., 2003;
Roepstorff et al., 2002; Zhuang et al., 2002).

1.3 Intracellular trafficking of cell surface molecules
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Recent studies show that cell surface receptors translocate from cell surface to
different cellular compartment, including the Golgi, mitochondria, endoplasmic
reticulum (ER), and the nucleus. These results indicate that the function of RTKs on
sub-cellular locations is more complicated than only down-regulate signal
transduction or recycle to the plasma membrane (von Zastrow and Sorkin, 2007).
Subcellular-localized cell surface proteins may play specific functions at different
cellular compartments (Figure 1-4).

Figure 1-4

Figure 1-4: Cell surface molecules localized on non-traditional organelles.
VEGFR, EGFR, MPR, TfR, and protein toxins have been reported to transport into the
Golgi apparatus. FGFR1 and EGFR have been reported to localize on the
mitochondria.

9

1.3.1 Golgi translocation of cell surface molecules
The Golgi apparatus is the first organelle where the cell surface molecules
have been detected. Early in 1980’s, non-specific plasma membrane markers such as
dextrans and cationized ferritin were found to translocate from cell surface to the
Golgi apparatus (Farquhar, 1985). This trafficking pathway was further supported by
the observation of other cell surface proteins including asialoglycoprotein receptor
(ASGPR) (Duncan and Kornfeld, 1988; Roth et al., 1985), transferrin receptor (TfR)
(Snider and Rogers, 1985), and mannose 6-phosphase receptor (MPR) (Jin et al.,
1989) translocated from plasma membrane to the Golgi apparatus. Further studies
have identified the transport of more cell surface proteins, such as G-proteins and
glycoprotein (Akgoz et al., 2004; Bos et al., 1995), to the Golgi apparatus.
Golgi-localized interferin receptor had been reported to regulate ligand uptake,
glycoprotein repair, or homeostasis of membrane compartment to balance the loss by
exocytosis (Snider and Rogers, 1985; Tauber et al., 1986; Tauber et al., 1983).
Recently, the specific functions of more cell surface receptors localized at the Golgi
apparatus were revealed. For example, Golgi localized VEGFR1 has been reported to
balance the level of VEGFR1 and VEGFR2 on plasma membrane and to dictate
endothelial signaling to influence vascular physiology (Mittar et al., 2009).
Perinuclear accumulation of cellular mesenchymal epithelial transition factor (c-Met)
was required for the downstream signaling (Kermorgant and Parker, 2008). However,
the functions of Golgi-translocated EGFR, TfR, and G-protein coupled receptors are
still unknown (Robertson et al., 1992; Saini et al., 2010; Wang et al., 2010a).
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Compared to less known function of cellular cell surface receptors on the
Golgi, foreign molecules such as bacterial protein toxins or viruses used Golgi
translocation to regulate their pathological function in target cells such as toxin
activity and viruses’ Ribonucleic acid (RNA) replication and assembly (Boulant et al.,
2008; Salanueva et al., 2003). For instance, the Golgi translocation of cholera toxin is
a critical step to activate the cyclic adenosine monophosphate (cAMP), thus cause
dehydration toxicity.

1.3.2 Translocation of cell surface molecules to mitochondria
Mitochondria are another cellular compartment on which cell surface
receptors had been detected. For example, EGFR or EGFR variant III (EGFRvIII)
transport to mitochondria to modulate the mitochondrial function via modification of
cytochrome oxidase subunit II (CoxII) (Demory et al., 2009; Yue et al., 2008) or to
cause resistance to drug treatment (Cao et al., 2011). Recent study indicated that
FGFR1 localized on mitochondria to phosphorylate the metabolic enzyme pyruvate
dehydrogenase kinase 1 (PDHK1) thus regulate mitochondrial activity in cancer cells
(Hitosugi et al., 2011).

1.3.3 Nuclear translocation of cell surface proteins
Many cell surface receptors, such as EGFR family including EGFR, ErbB2,
ErbB3, and ErbB4, VEGFR1, FGFR, c-Met, and insulin-like growth factor 1 receptor
(IGF1R) (Feng et al., 1999; Kermorgant and Parker, 2008; Marti et al., 1991; Sehat et
al., 2010; Stachowiak et al., 1996b; Wang and Hung, 2009) had been reported to
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translocate into the nucleus and play important physiological and pathological roles
(Figure 1-5). G protein-coupled receptors, such as tachykinin neurokinin 3 receptor
(NK3R) (Jensen et al., 2008) and endothelin receptors (Boivin et al., 2003), are
another type of cell surface receptors which have been detected in the nucleus.

Figure 1-5

Figure 1-5: Cell surface receptors transport into the nucleus. RTKs including
EGFR family, VEGFR1, FGFR and c-Met have been detected in the nucleus. G
protein coupled receptors are reported to transport to the nucleus.
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1.3.3.1 Nuclear translocation of EGFR family
All EGFR family including EGFR, ErbB2, ErbB3, and ErbB4 have been
detected in the nucleus in different cell types and human cancers (Wang and Hung,
2009; Wang et al., 2010b). EGFR is a well-investigated RTK that is translocated into
the nucleus from the cell surface in response to ligand stimulation or under certain
stress conditions, such as ultraviolet or ionizing radiation (Dittmann et al., 2005; Lin
et al., 2001; Xu et al., 2009). EGFR also exists in the nucleus in different human
tissue and cancer cell types (Li et al., 2010; Marti et al., 1991; Psyrri et al., 2008;
Raper et al., 1987; Xia et al., 2009). Multiple laboratories have reported the
correlation between nuclear expression of EGFR (nEGFR) and poor prognosis for
several different cancer types in humans (Hadzisejdic et al., 2010; Hoshino et al.,
2007; Lo et al., 2005b; Psyrri et al., 2005; Xia et al., 2009). Also, functional studies
have revealed that nEGFR functions as a transcriptional co-factor to regulate target
gene expression in an EGF-dependent manner and promote cell proliferation (Huo et
al., 2010; Lin et al., 2001; Lo and Hung, 2006). Transcriptional regulation of nEGFR
is mediated by a DNA-binding domain-containing RNA helicase A to recognize a
specific AT-rich sequence in the promoter regions of targeted genes. nEGFR can also
interact with other co-regulators, such as signal transducers and activators of
transcription protein 3 (STAT3), STAT5, heterodimeric transmembrane mucin
(MUC1), and epstein-barr virus (EBV)-encoded latent membrane protein 1, to
regulate gene expression (Bitler et al., 2010 ; Hung et al., 2008; Huo et al., 2010;
Jaganathan et al., 2011; Lo et al., 2005a; Tao et al., 2005). Furthermore, nEGFR is
involved in the regulation of deoxyribonucleic acid (DNA) replication and repair
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(Chen and Nirodi, 2007; Das et al., 2007; Dittmann et al., 2008; Wang et al., 2006).
More recently, nEGFR was found to contribute to the resistance to cetuximab, a
monoclonal antibody against EGFR, and gefitinib, a tyrosine kinase inhibitor (Huang
et al., 2011; Li et al., 2009). All of studies that shed light on the nuclear functions of
EGFR may provide important clues about its potential clinical applications.
ErbB2 is another well studied receptor in the nucleus. Nuclear ErbB2 has been
reported to function as a transcriptional regulator via binding to the promoter of
cyclooxygenase-2 (COX-2) (Wang et al., 2004). Recent study has been shown that
nuclear ErbB2 associates with β-actin and RNA polymerase I to enhance the rRNA
transcription (Li et al., 2011). Not only the full length of ErbB2 can transport into the
nucleus, but truncated form of ErbB-2 is also detected in the nucleus and contributes
to the resistance of anti-HER2-targeting therapies (Scaltriti et al., 2007).
The clinical studies indicated that nuclear ErbB3 is correlated with prostate
cancer disease progression (Cheng et al., 2007; Koumakpayi et al., 2006). A nuclear
variant of ErbB3 has been shown to regulate myelination of Schwann cell
(Adilakshmi et al., 2011).
ErbB4 is a well recognized cell surface receptor to transport into the nucleus
as truncated form which associates with transcriptional factor STAT 5A at the βcasein promoter and thus regulates the activation of STAT 5A-stimulated gene
(Williams et al., 2004). Furthermore, the fragment of ErbB-4 can function as a kinase
to phosphorylate Mdm2 and to increase the ubiquitination of Mdm2. As results, ICD
of ErbB4 enhances the protein levels of p53, p21, and transcriptional target of p53
(Arasada and Carpenter, 2005).
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1.3.3.2 Nuclear translocation of VEGFR
VEGFR2 (FIk/KDR) is the receptor of VEGF-A. It has been detected in the
nucleus and functions to regulate the activation of transcription factors (Feng et al.,
1999) or to form a complex with transglutaminase II (tTG) and mediate the response
to VEGF stimulation (Dardik and Inbal, 2006).

1.3.3.3 Nuclear translocation of FGFR-1
FGFR-1 is another well-studied tyrosine kinase receptor which can be
accumulated in the nucleus (Bryant and Stow, 2005; Johnston et al., 1995;
Stachowiak et al., 1996a, b) and functions as a transcriptional regulator. Nuclear
FGFR1 induces the expression of c-Jun and serves as a common co-activator to
activate cAMP response element-binding (CREB)-binding protein and regulate cell
proliferation (Reilly and Maher, 2001). Nuclear FGFR1 is also involved in neuronal
differentiation via mediation of cAMP and morphogenetic protein 7 (BMP-7)
(Horbinski et al., 2002).

1.3.3.4 Nuclear translocation of other molecules
Other cell surface proteins, such as G proteins coupled receptors angiotensin I,
II, endothelin, NK3R, and bradykinin, are detected in the nucleus (Chen et al., 2000;
Lee et al., 2004). But their functions remain largely unknown. Nuclear translocation
of NK3R occurs upon osmotic challenge (Jensen et al., 2008) and nuclear endothelin
receptor is coupled with the signaling transduction machinery within the nuclear
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membrane (Boivin et al., 2003). Although most nuclear G protein coupled receptors
function to regulate signaling pathways which is similar to its function on the cell
surface, some of them, such as nuclear PTH/PTHrP receptor, β-adrenergic receptor,
and metabotropic glutamate receptor 5 (mGluR5), can directly regulate cell
proliferation (Watson et al., 2000), transcriptional initiation (Boivin et al., 2006),
gene expression (Jong et al., 2009; Savard et al., 2008; Vaniotis et al., 2011), and
histone modification (Re et al., 2010). Recently, the extracellular matrix receptor βdystroglycan (β-DG) has been detected in the nucleus. But the function of nuclear βDG needs to be further investigated (Oppizzi et al., 2008).
More recently, membrane-anchored cell surface protein Heparin-binding
EGF-like growth factor (HB-EGF) and its precursor proHB-EGF have been reported
to transport to the inner nuclear membrane in response to stresses (Hieda et al., 2008;
Kim et al., 2005). The studies of their nuclear translocation indicated that releasing
from the cell surface membrane is not required for the nuclear translocation of cell
surface proteins.

1.3.4 Mechanisms of intracellular trafficking
Investigation of mechanisms regulating intracellular trafficking of cell surface
receptors is critical for further understanding of their functions at cellular
compartment. However, the mechanism of how cellular proteins translocate to
mitochondrial is not clear at all. The trafficking pathway of cellular proteins from cell
surface to the Golgi apparatus is largely unknown although the studies of the Golgi
translocation of bacterial protein toxins led to the identification of several regulators
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mediating this trafficking pathway (Spooner et al., 2006). For example, the transport
of shiga toxin from early endosomes to the Golgi apparatus is regulated by a series of
soluble NSF attachment protein receptor (SNARE) and a small guanosine
triphosphate (GTP) GTPase Rab6 isoform.
Because of the importance of cell surface receptors in the nucleus, uncovering
the mechanisms of their nuclear translocation become very attractive. A proteasedependent mechanism shown in Figure 1-6 was proposed to address how these
integrated receptors are released from the lipid bilayer.

Figure 1-6

Figure 1-6: The mechanism of nuclear translocation of cell surface receptors.
Truncated form of cell surface receptors is an accepted mechanism to explain how cell
surface receptors transport into the nucleus. RSK-1 mediates releasing of FGFR1 from
cell surface to the cytoplasm is another mechanism to explain nuclear translocation of
FGFR1. Endocytosis is required for nuclear transport of ErbB2 and EGFR. Sec61
located either on ER membrane or inner nuclear membrane is involved in nuclear
translocation of EGFR.
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According to this mechanism, the translocation of transmembrane receptors
into the nucleus is caused by the interaction of a nuclear import protein with the
intracellular fragments of receptors. For example, in the nuclear translocation of
ErbB4 (Ni et al., 2001), γ-secretase cleavages ErbB4 and releases the truncated form
(intracellular domain (ICD)) of ErbB4 from membrane and then transport into the
nucleus as a soluble protein. Similarly, β-secretase cleaves β-amyloid precursor
protein (APP) and releases soluble fragment, an amyloid β peptide (Aβ) that is critical
for Alzheimer’s disease (Vassar et al., 1999). Proteolysis-mediated activation of
Notch receptor is another sample (Maillard et al., 2005), in which the intracellular
domain of Notch is released by ligands induced proteolytic cascade and then
translocates to the nucleus to regulate the transcription of targeted genes.
Although some cell surface receptors translocate into the nucleus as soluble
truncated form as mentioned above, most cell surface receptors detected in the
nucleus are full length proteins. It has been reported that 90-kDa ribosomal S6 kinase
(RSK1) (Hu et al., 2004) can directly release the full length of FGFR1 from plasma
membrane and then into the nucleus. However, another report showed that endosomal
trafficking is still required for the nuclear translocation of FGFR1 (Bryant et al.,
2005).
The mechanism of nuclear translocation of EGFR and ErbB2 is well-studied.
It has been reported that endocytosis is required for the nuclear translocation of
EGFR and ErbB2 because blocking of endocytosis using a dominant negative
mutation of dynamin or endocytosis inhibitors can decrease their nuclear
translocation (Giri et al., 2005; Lo et al., 2006). The involvement of importin 1/1, a
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critical molecule for the nucleus/cytoplasm shuttling, in the nuclear transport of
EGFR and ErbB2 and the identification of nuclear location signal (NLS) in EGFR
and ErbB2 (Hsu and Hung, 2007) indicated that the nuclear transport of EGFR or
ErbB2 is regulated by nucleus/cytoplasm shuttling machinery. Translocon Sec61
localized either on the ER or inner nuclear membrane plays an important role in the
release of EGFR or ErbB2 from cell surface or membrane compartment (Giri et al.,
2005; Hsu and Hung, 2007; Liao and Carpenter, 2007; Wang et al., 2010a; Wang et
al., 2010c). Recent studies demonstrated that coatomer protein I (COPI), which
regulates the trafficking from the Golgi to ER, also functions for the nuclear
trafficking of EGFR. This finding suggest that the machinery mediating the
retrograde trafficking is also involved in the nuclear translocation of EGFR and
membrane trafficking may be an important biological event to regulate the nuclear
translocation of EGFR or other cell surface transmembrane receptors via membrane
compartments.

1.4 Retrograde trafficking
After synthesis and post-transcription, proteins are delivered to the targeted
cellular locations via exocytosis or secretory system including a series of membrane
compartments (Burgoyne and Morgan, 2003) (Figure 1-7). In opposite, retrograde
transport, an influx of proteins and lipids, is used to balance the outward flow of
secretion. Retrograde trafficking is thought to from endosomal components including
early endosomes and late endosomes or from the recycling endosomal compartments
to the endoplasmic reticulum (ER) or the Golgi apparatus (Johannes and Popoff,
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2008). Similar to endocytosis, adaptor proteins, such as AP-1 and coated proteins
clathrin, are involved in the initiation of retrograde trafficking. Small GTPases such
as Rab proteins are important for intracellular trafficking pathway. Different Rabs
coordinates with other cofactors to tether and dock cargo proteins or vesicles
containing transferred materials. It has been demonstrated that Rab6, Rab9, and
Rab11 regulate retrograde trafficking from different endosomal compartments.

Figure 1-7

Figure 1-7: Retrograde trafficking pathway. Retrograde trafficking includes
intracellular trafficking events from different endosome (early, late, recycling) to the
Golgi apparatus. Adaptor proteins such as AP-1 and epsinR, membrane coat proteins
such as clathrin, or the retromer complex are involve in the formation of intermediates
containing cargo proteins. Tethering, docking, and fusion of retrograde transport
intermediates with the TGN depend on a wide range of regulatory factors, such as
golgin-97, golgin-245, GCC88, and GCC185. SNARE (soluble N-ethylmaleimidesensitive fusion factor attachment receptor) complexes are required for membrane
fusion.
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1.5 SNARE proteins and membrane fusion
Membrane fusion is an important biological event occurring between cells,
different intracellular compartments, intracellular compartments, and the plasma
membrane (Bonifacino and Glick, 2004; Jahn and Scheller, 2006; Pfeffer, 2007).
Studies of membrane fusion between vesicles and organelles have mainly focused on
neural synaptic vesicles fusion (Hirokawa and Takemura, 2005) or endocytic
pathways (Chernomordik and Kozlov, 2003; Soldati and Schliwa, 2006). The proteins
that mediate membrane fusion include SNAREs, synaptotagmins, and viral fusion
proteins (Martens and McMahon, 2008). SNARE family proteins are critical players
for the intracellular events. In general, four SNARE proteins localized at different
compartments are assembled to initiate the membrane fusion and to complete the
organelles’ transport and the delivery of cargo proteins from one compartment to
another compartment (Jahn and Scheller, 2006).
There are two types of SNAREs proteins, vesicle SNAREs (v-SNAREs) and
target SNAREs (t-SNAREs).

v-SNAREs localize in vesicles or other forms of

transport intermediates and t-SNAREs localize in the target compartment. The tSNARE family members have two sub-classifications, heavy and light chains (Hong,
2005). Different SNARE proteins functions at different organelles to regulate the
vesicular transport of cargo proteins. For example, v-SNARE proteins, vesicleassociated membrane protein (VAMP) 3, VAMP4, and VAMP5 localize on the
plasma membrane. They can be internalized into cytoplasm in endosomes or vesicles
(Tran et al., 2007; Zeng et al., 2003). T-SNARE proteins syntaxin 6, syntaxin 16, and
vti1a localize on the trans-Golgi network or the endoplamic reticulum and assemble
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to initiate the fusion of small vesicles with organelles (Mallard et al., 2002; Zwilling et
al., 2007).
The machinery of retrograde trafficking pathway from cell surface and

endosomes to the trans-Golgi network has been well-studied (Bonifacino and Rojas,
2006). Although a comprehensive retrograde trafficking pathway has been uncovered
and regulators and factors, such as adaptor proteins, small GTPase, coating protein,
tethering factor, and SNARE proteins have been identified, only a few cellular
proteins such as transferrin receptor and mannose 6-phosphate receptor and foreign
protein such as protein toxins or viruses have been reported as a cargo protein
regulated by retrograde trafficking pathway (Green and Kelly, 1990; Roth, 1987;
Snider and Rogers, 1985). Clearly there is a big gap between retrograde trafficking
pathway and other important cellular events, such as signaling transduction.
The focus of our study is to link retrograde trafficking pathway with noncanonical EGFR signaling and to investigate the mechanism of how EGFR
translocate from cell surface to the Golgi and the nucleus and thus functions as a
transcriptional regulator. Syntaxin 6 is a well-known SNARE protein that regulates
endosomal trafficking via membrane fusion in the retrograde trafficking pathway
(Figure1-7) (Jahn and Scheller, 2006; Johannes and Popoff, 2008; Martens and
McMahon, 2008). Thus the role of syntaxin 6 in the trafficking of EGFR to the Golgi
and nucleus is systematically investigated in our study.

1.6 Microtubule dependent intracellular trafficking
1.6.1 Microtubule cytoskeleton
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Microtubules are a component of cytoskeleton. They serve as structural
components within cells and are involved in many cellular processes including
proliferative divisions and vesicular transport (Kelly, 1990). Microtubules are
polymers of α- and β-tubulin dimers. The tubulin dimers polymerize end to end into
protofilaments with α subunit and β subunit from different dimers. Protofilaments
then bundle in hollow cylindrical filaments. Another important feature of microtubule
structure is its polarity. In a microtubule, there is one (+) end with only β subunits
exposed while the other (−) end has α subunits exposed. Usually, the (+) end is close
to the cell surface and the (−) end is close to the nucleus (Nogales, 2000). In most
cells, especially in the non-polarized cells, microtubules are nucleated and organized
by the microtubule organizing centers (MTOC) (Cole and Lippincott-Schwartz, 1995;
Rodriguez-Boulan et al., 2005), such as centrosomes, which usually locate near the
nucleus and associate closely with the Golgi apparatus.
The critical role of microtubules during the transport of organelles and
vesicles has been well studied and understood (Rogers and Gelfand, 2000).
Microtubules provide the basis for the directional movement of organelles and
vesicles. The specific motor proteins (Hirokawa and Takemura, 2005; Mallik and
Gross, 2004), fusion proteins (Hong, 2005; Jahn and Scheller, 2006), and small
GTPases (Grosshans et al., 2006; Schwartz et al., 2007) decide the direction and
specificity. Microtubules also provide the roadway for the movement of the protein
cargo. For example, intact microtubules have been shown to be necessary for the
nuclear translocation of glucocorticoid receptor (GR) (Galigniana et al., 2004; Harrell
et al., 2004). Overexpression of dynamitin which inhibits the function of dynein could
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block the nuclear translocation of GR (Burkhardt et al., 1997; Melkonian et al., 2007).
Moreover, microtubules function in the distribution of virus particles during the virus
maturation (Boulant et al., 2008) and the transport of herpes simplex virus 1 into the
nucleus (Sodeik et al., 1997). Another function of microtubules is to regulate the
subcellular localization of mRNA (Messitt et al., 2008; Zimyanin et al., 2008).
Microtubules are also an important component during the endocytic trafficking. Some
studies have shown that intracellular transport of cargo proteins requires the
cytoskeleton including microtubules and motor proteins (Allan and Schroer, 1999;
Cole and Lippincott-Schwartz, 1995).

1.6.2 Microtubule motor proteins
Motor proteins are another kind of molecules regulating the microtubuledependent movement (Figure 1-8). Dynein and kinesin are two major motor proteins
utilized for the trafficking of cargo along the microtubules. The difference between
these two motor proteins is the direction of the movement of cargo (Schliwa and
Woehlke, 2003). Kinesin delivers cargo from inside of cells to the cell surface and
dynein transports cargo from cell surface to the center of cells (Caviston and
Holzbaur, 2006; Hirokawa and Takemura, 2005).
Dynein is composed of heavy chains, light chains, and intermediate chains
(Porter and Johnson, 1989). It carries the cargo proteins and moves along
microtubules utilizing different functional domains such as the cargo binding domain,
ATPase domain, and the microtubules binding domain. Dynein provides the energy
for the minus-end movement of cargoes or vesicles along microtubules (Ross et al.,
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2008). Dynactin is another complex which helps dynein to complete its function
(Schroer, 2004).
Figure 1-8

Figure 1-8: Motor proteins involved in intracellular transport of cargo proteins.
Microtubule motor proteins dynein and kinesin regulate the direction of the movement
of cargo along the microtubules. Myosin functions as a motor for trafficking along
actin filements.

There are two groups of dynein: cytoplasmic dynein and axonemal dynein.
Cytoplasmic dynein is necessary for organelles transport and centrosome assembly.
Axonemal dynein functions in the sliding of the microtubule in the axonemes of cilia
and flagella. Cytoplasmic dynein is a motor protein which provides the power for the
movement along microtubules.
As described above, intracellular transport of cargo proteins requires the
cytoskeleton including microtubules (MTs) and motor proteins (Allan and Schroer,
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1999; Cole and Lippincott-Schwartz, 1995). More recent studies demonstrated that
microtubule-dependent intracellular trafficking is used for EGFR degradation (Deribe
et al., 2009; Gao et al., 2010). Moreover, although a plenty of data have shown that
cytoskeleton provides the real pathway for the movement of vesicles, endosomes, and
organelles in the cytoplasm (Allan and Schroer, 1999; Bananis et al., 2000; Murray et
al., 2000; Rodriguez-Boulan et al., 2005), there are limited studies addressing the
relationship between nuclear trafficking of endocytic cell surface receptors and
cytoskeletons. Therefore, in the present study, we investigated the roles of
microtubules and motor proteins in the Golgi and nuclear translocation of EGFR.
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Chapter Two
Materials and Methods
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2.1 Chemicals and antibodies
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO). The
following antibodies were used in this study: anti-EGFR (Santa Cruz Biotechnology,
Inc. Santa Cruz, CA and Neomarkers, Fremont, CA); anti-dynein IC (Santa Cruz
Biotechnology, Inc. Santa Cruz); anti-tubulin (Abcam, Cambridge, MA; SigmaAldrich Co. St. Louis, MO); anti-syntaxin6 (BD Bioscience, San Jose, CA); antilamin B (Calbiochem, San Diego, CA); anti-calregulin (Santa Cruz Biotechnology,
Inc. Santa Cruz); anti-vacuolar protein-sorting (vps) vps10p tail interacting 1a (Vti1a)
(BD Bioscience, San Jose, CA); anti-actin, anti-myc and anti-HA (Roche,
Indianapolis, IN). All fluorescence-labeled secondary antibodies were obtained from
Invitrogen (Carlsbad, CA).

2.2 Cell culture and treatment
All cells lines were maintained in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 medium supplemented with 10% fetal bovine serum and antibiotics.
Cells were serum-starved overnight or 12 hr before EGF stimulation. For experiments
using inhibitors, serum starved cells were treated with inhibitors first and then
stimulated with EGF.

2.3 Plasmid constructs, small interfering RNA oligonucleotides, and short
hairpin RNA
The syntaxin 6 full-length plasmid was purchased from the Origene. The coilcoiled domain of syntaxin6 was subcloned into the pcDNA6His-MycA (Invitrogen,
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Carlsbad, CA) and pDsRedC1 (Clontech, Mountain View, CA) for fluorescence
staining. The GalNAc-T2-GFP plasmid was a gift from Dr. B. Storrie (University of
Arkansas for Medical Sciences). The plasmid expressing cyclin dependent kinase 1
(CDK1) (#1888), cyclin B (#10911), and RFP-tubulin (#21041) were obtained from
Addgene. pEGFP-EGFR was constructed by subcloning full length EGFR into the
pEGFP-N1 (Clontech, Mountain View, CA) with HindIII and KpnI.
siRNA

oligonucleotides

targeting

dynein

IC

(siRNA

ID:

SASI_Hs01_00129737 and SASI_Hs01_00129739), syntaxin 6 (siRNA ID:
SASI_Hs01_00129146 and SASI_Hs01_00129147), non-specific siRNA control
(Hurtado

et

al.,

2008)

(containing

the

sequences

5’-

AUCACAUCUGUCAAAUUAUU-3’, 5’-GAACGUGGCUCUCAAAGUUU-3’, 5’AAAGGAAAUCGACACUGAUU-3’ and 5’-GCCCUGGGAUUUAUGAUGAUU3’), and short hairpin RNA (shRNA) targeting dynein IC (TRCN0000116797 and
TRCN0000116799) were purchased from Sigma-Aldrich (St. Louis, MO). For small
interfering RNA (siRNA) transfection, the siRNAs were transfected into cells using
the cationic liposome SN (Stabilized Non-viral) or lipofectamine 2000 (Invitrogen,
Carlsbad, CA) as previously described (Yan et al., 2004). Briefly, cells were grown
overnight and incubated with plasmid/liposome complexes in Opti-MEM medium for
4 hr, followed by replacement of complete medium and incubation at 37°C for 24 to
48 h. pLKO based shRNA was co-transfected with packaging vector and envelope
vector into A293T cells for virus production. After 48 hr transfection, media
containing lentivirus were harvested by centrifugation. Media were further filtered by
0.45 μM filter and used to infect target cells.
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2.4 Nuclear fractionation
Treated cells were collected, washed with ice-cold phosphate buffered saline
(PBS), swelled, and solublized in lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM KCl,
0.5%

NP-40

2mM

MgCl2,

0.5

mM

dithiothreitol

(DTT),

1

mM

phenylmethanesulfonylfluoride or phenylmethylsulfonyl fluoride (PMSF), and 0.15
u/ml aprotinin) for 20 min on ice. After cells were homogenized with a Dounce
homogenizer (20 strokes) on ice, the nuclei were pelleted by centrifugation at 600 x g
for 5 min, and then the supernatant was collected as cytoplasmic fraction. The nuclei
pellet was washed with lysis buffer 3 times to remove any cytoplasmic contamination.
Finally, the nuclei pellet was solubilized in the Radio Immuno Precipitation Assay
(RIPA) buffer (10 mM Tris•HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS, 0.5 mM DTT, 1 mM PMSF, and 0.15 u/ml aprotinin), and
sonicated to disrupt all nuclei, followed by centrifugation at 16,000 ×g for 20 min at
4°C. The supernatant was collected as nuclear lysate.

2.5 Purification of the Golgi apparatus
The Golgi apparatus were purified using the OptiPrep density gradient
medium by following the manufacturer’s guidelines with a slight modification
(Sigma-Aldrich, St. Louis, MO). Briefly, cultured cells were harvested and
resuspended in a homogenization buffer (10 mM Hepes, pH 8.0, 250 mM sucrose,
140 mM NaCl, and protease inhibitor cocktail). Cells were homogenized using 20
strokes with a Dounce homogenizer in the same buffer and then centrifuged at 800× g
for 5 min at 4°C. The supernatant was collected and then loaded onto continuous
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iodixanol gradients from 0% to 30% and centrifuged at 48,000× g for 16 hr at 4°C.
The gradients were unloaded in 0.6 ml fractions. Markers for the Golgi apparatus,
early endosome, and ER in each fraction were analyzed.

2.6 Immunoprecipitation and immunoblotting
For immunoprecipitation (IP) experiments, cytoplasmic fractions of HeLa
cells were treated as described above and precleared with 1 g of mouse or rabbit IgG
and 20 l of protein G-agarose (Roche, Indianapolis, IN) for 1 hr at 4°C. Precleared
lysates were then incubated with 1 g of primary antibodies or mouse IgG at 4°C
overnight with gentle agitation. Following the addition of protein G-agarose,
incubation was continued for an additional 30 min at 4°C. Protein G-agarose pellets
were

collected

and

washed

for

multiple

cycles

at

4°C.

The

washed

immunoprecipitates were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blot analysis as previously described (Giri
et al., 2005).

2.7 Chromatin IP (ChIP)
Chromatin immunoprecipitation (ChIP) was performed by following the
manufacturer’s guidelines. In brief, treated cells were fixed with 1% high quality of
formaldehyde for 10 minutes at room temperature. Then cells were lysated with lysis
buffer and then sonicated to shear the genome DNA to manageable fragments. Lysis
were precleared with protein G agarose and then incubated with indicated antibody or
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IgG control. DNA was isolated with the EZ-ChIP kit and subjected to polymerase
chain reaction (PCR) to analyze relative level of target genes.

2.8 Confocal microscopy analysis
For fixed cells, all experiments were performed as previously described (Giri
et al., 2005). Briefly, cells grown on chamber slides (Labtek, Scotts Valley, CA) were
treated as described above. After washing with ice-cold PBS, cells were fixed,
permeabilized, and incubated with primary antibodies and fluorescence-labeled
secondary antibodies. Immunostained cells were examined using an Olympus
FluoView FV300 confocal microscope (Olympus America, Melville, LA) or Zeiss
LSM 710 laser-scanning microscope (Carl Zeiss, Inc. Thornwood, NY) with a
63X/1.4 objective. For live cell imaging, HeLa cells were grown in 35-mm glassbottomed dishes (MatTek Corporation, Ashland, MA). Imaging was performed using
the Zeiss LSM 710 microscope with a 37°C incubation chamber using a 40X/1.2 NA
objective. A laser (488 and 561 nm) was used to obtain the images. EGFR was
labeled with EGFP, tubulin was labeled with mRFP, and syntaxin 6 was labeled with
DsRed. After 48 hr of transfection, cells were serum-starved overnight. After EGF
stimulation, cells were monitored with 30 min time lapse and 15 seconds interval
(EGFR and microtubules); 40 minutes time lapse and 20 second interval (EGFR and
syntaxin 6). The ZEN and AxioVison software programs (Carl Zeiss MicroImaging,
Inc., Thornwood, NY) and ImageJ software program (National Institutes of Health,
Bethesda, MD) were used for data analysis.

32

2.9 Fluorescence resonance energy transfer (FRET)
HeLa cells were transfected with pEGFP-EGFR (donor) for 48 hr. Cells were
exposed to serum-free medium overnight, treated with EGF (50ng/ml) for 30min
following fixation overnight at 4°C with 4% paraformaldehyde (PFA), and then
washed three times with PBS. Cells were incubated with 0.05% Triton X-100 for 15
min and washed with PBS three times. Cells were blocked with 3% bovine serum
albumin (BSA) in PBS and incubated with primary mouse anti-α-tubulin antibody
and secondary mouse Alexa Fluor-555 antibody (acceptor). The slides were examined
with Zeiss LSM710 confocal microscope (Carl Zeiss MicroImaging, Inc., Thornwood,
NY). For FRET data acquisition, three channels were set-up: Donor (GFP), Acceptor
(Alexa Fluor 555), and the FRET channel. The donor channel has a 488nm excitation
and 495-525nm emission collection and the acceptor channel has a 561nm excitation
and 575-635nm emission collection. In contrast, the FRET channel has a 488nm
donor-excitation and 575-635nm acceptor emission collection in order to image
acceptor emission resulted from energy transferred from the donor. Then optimal
laser power levels and PMT settings were determined for the double-labeled sample
to avoid photobleaching and saturation in all three imaging channels. After
optimization, nine images were acquired for background and spectral bleed-through
correction and subsequent FRET analysis from single-label donor sample, singlelabel acceptor sample, and double-label sample containing donor and acceptor
fluorophore. For analysis of FRET efficiency quantitatively, Youvan method was
chose to calculate the raw FRET images based on the following formula and a colorcoded FRET image was then created.
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Fc= (fretgv-bg fret)-cfdon*(dongv-bgdon)-cfacc*(accgv-bgacc)
Fc: FRET as calculated by the Youvan method
gv: intensity as gray value
bg: background intensity
cf: correction factor
fret: raw fret-channel image
don: donor channel image
acc: acceptor channel image

2.10 Immunoelectron microscopy (Immuno-EM)
Cells were fixed with 2% paraformaldehyde containing 0.1% glutaraldehyde
for 1 hr, permeabilized with 0.5% Triton X-100 for 15 min, and then incubated with
5% bovine serum albumin for 15 min. After overnight incubation at 4°C with primary
antibodies, cells were then washed with PBS and further incubated with the gold
particle-labeled secondary antibody (Electron microscopy science, Hatfield, PA)
overnight at 4°C for immunogold labeling. After post-fixation with 2%
glutaraldehyde, cells were washed and stained with 1% Millipore-filtered uranyl
acetate. The samples were dehydrated in increasing concentrations of ethanol,
infiltrated, and embedded in Spurr’s low viscosity medium. The samples were
polymerized in a 70°C oven for 2 days. The glass cover slips were removed by
dipping the blocks in liquid nitrogen. Ultrathin sections were cut with a Leica
Ultracut microtome (Leica, Deerfield, IL), stained with uranyl acetate and lead citrate
in a Leica EM Stainer, and examined using a JEM 1010 transmission electron
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microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage of 80 kV.
Digital images were obtained using an AMT Imaging System (Advanced Microscopy
Techniques Corp, Danvers, MA).

2.11 RT-PCR and quantitative real-time PCR
First-strand cDNA was obtained from 1 μg of total RNA isolated with the
Trizol Reagent (15596-026, Invitrogen, Carlsbad, CA) using the SuperScript III FirstStrand Synthesis System (18080-051, Invitrogen) and oligo(dT)20 primers. For RTPCR, primers (5’-GTCATGGGAGAAAACAACAC-3’and 5’- CTTTGCCTC
CTTCTGCATGG-3’) were used to amplify the EGFR gene fragment. The PCR was
performed in a total volume of 20 μl Taq reaction buffer containing 6 nmol dNTPs,
20 pmol of each primer, 1 μl Dimethyl sulfoxide (DMSO), and 0.2 μl Taq
polymerase. The PCR cycling conditions were as follows: one cycle at 94°C for 5
min; 30 cycles of 94°C for 45 s, 57°C for 45 s, and 72°C for 1 min; and a final
extension cycle at 72°C for 10 min. For quantitative RT-PCR, the cDNAs were
amplified in iQ SYBR Green Supermix (170-8880, Bio-Rad, Hercules, CA). The
relative amount of mRNA was determined by performing RT-PCR in triplicate using
specific

primers

with

the

following

sequences:

GAPDH

forward,

5’-

GGTGGTCTCCTCTGACTTCAACA -3’; and GAPDH reverse, 5’-GTTGCTGTAG
CCAAATTCGTTGT-3’. ACTB forward: 5’-GTTGTCGACGACGAGCG-3’, ACTB
reverse 5’-GCACAGAGCCTCGCCTT-3’

2.12 Luciferase reporter assay
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HeLa cells plated in 12-well culture plates were transfected with pCCD1-Luc
and the control Recilla luciferase reporter construct pRL-TK (Promega) as previously
described (Lo et al., 2005a). Twenty-four hours following transfection, cells were
serum starved overnight, stimulated with 100 ng/ml EGF for indicated time,
harvested, and subjected to luciferase assay using the dual luciferase assay kit and the
TD20/20 luminometer (Promega, Madison, WI). Following normalization with the
Recilla luciferase activity (transfection efficiency control), mean luciferase activities
and standard deviations were derived from three independent experiments.
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Chapter Three
Syntaxin 6-mediated Golgi trafficking regulates
transcriptional activity of nuclear EGFR
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3.1 EGF induces translocation of EGFR to the Golgi apparatus
3.1.1 EGF stimulation enhances the protein level of EGFR in the Golgi-enriched
fraction
It has been shown that retrograde trafficking from Golgi to ER is required for
the nuclear translocation of EGFR (Wang et al., 2010a). However, it is not yet clear
how EGFR moves from cell surface to the Golgi apparatus. To address this issue, we
first asked whether EGFR transport to the Golgi could be stimulated by its ligand,
EGF. We separated the Golgi apparatus using iodixanol density gradient
ultracentrifugation and examined the presence of EGFR in the Golgi- enriched
fraction. As shown in the top panel of Figure 3-1, left panel, using two Golgi
apparatus markers, syntaxin 6 and Vtl1b, we found that fraction 9 was the Golgienriched fraction from normal culture condition. EGFR expression level in the Golgienriched fraction was significantly higher in cells treated with EGF than that in cells
without EGF treatment (Figure 3-1, right panel).
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Figure 3-1

Figure 3-1: EGF induces translocation of EGFR to the Golgi apparatus. (Top)
The 0-30% OptiPrep continuous density gradient was constructed using the Gradient
Station (BIOCOMP, Fredericton, NB). Cell lysate in normal culture was loaded onto a
density gradient medium and subjected to ultracentrifugation, and fractions were
separated using the Gradient Station. The early endosome, the Golgi, and ER markers
were used to analyze fractions. (right) HeLa cells were treated with or without EGF
(50 ng/ml) for 20 min after starvation overnight. The EGFR level in the Golgienriched fraction (fraction 9) was analyzed using immunoblotting.

3.1.2 EGF induces the colocalization of EGFR with the Golgi marker
Polypeptide N-acetylgalactosaminyl transferase 2 (GalNac T2) (Storrie et al.,
1998) is another marker of the Golgi apparatus. Using confocal microscopy analysis,
we detected the localization of EGFR on the GalNac T2 positive compartment under
a time-course treatment of EGF indicating that EGFR was on the Golgi apparatus.
The colocalization peaked at 30 min and then gradually decreased at 60 min post EGF
stimulation (Figure 3-2). We quantified the colocalization of EGFR with GalNac T2
by counting the numbers of yellow spots that resulted from the merge of the green
signal of EGFR with the red signal of GalNac T2 (right panel of Figure 3-2). These
results indicated that EGFR colocalized with the Golgi apparatus, which is in
consistent with biochemical results shown in Figure 3-1.
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Figure 3-2

Figure 3-2: EGF stimulates the colocalization of EGFR with the Golgi marker
GalNac T2. HeLa cells were transfected with GalNac T2 expression plasmid. Cells
maintained in serum-free media overnight were treated with EGF (50 ng/ml) for the
indicated time. The colocalization of EGFR with GalNac T2 was examined with
confocal microscopy. All nuclei were confirmed by DAPI staining. Green, red, and
blue channels: EGFR, GalNac T2, and nuclei, respectively. Scale bars, 20 m.
Quantitation of cells with nEGFR are shown in the right panel.

3.1.3 Inhibition of protein synthesis does not affect EGF-induced Golgi
translocation
To rule out the possibility that EGF stimulation induces EGFR synthesis in the
ER and its posttranslational modification at the Golgi apparatus, we treated HeLa
cells with protein synthesis inhibitor, cycloheximide (CHX), for 6 hr and still
observed the colocalization of EGFR with GalNac T2 upon EGF stimulation (Figure
3-3), indicating that EGF can induce translocation of EGFR to the Golgi apparatus in
the absence of protein synthesis. This notion was further supported by our
observation that the EGFR protein and mRNA levels did not change significantly
upon treatment with EGF for 30 min (Figures 3-4).
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Figure 3-3

Figure 3-3: Inhibition of protein synthesis does not affect EGF-induced nuclear
translocation of EGFR. HeLa cells were transfected with a plasmid encoding EGFPGalNac T2, and cells were exposed to serum-free media overnight following
treatment with EGF (50 ng/ml) for 20 min with and without CHX treatment. The
colocalization of EGFR with GalNac T2 was examined with confocal microscopy.
All nuclei were confirmed by DAPI staining. Green, red, and blue channels: EGFR,
GalNac T2, and nuclei, respectively. Scale bars, 20 m. The boxed areas are shown in
detail in the insets. Quantitation of positive cells with nEGFR is shown in the lower
panel. DMSO, dimethyl sulfoxide; CHX, cycloheximide, a protein synthesis inhibitor.

Figure 3-4

Figure 3-4: EGF stimulation does not change the protein and mRNA level of
EGFR. HeLa cells were treated with EGF for different time. Total lysates were
examined by immunoblotting analysis with indicated antibodies. Total mRNA
isolated from cells was reversed transcribed to cDNA. mRNA level of EGFR and
GAPDH were examined by RT-PCR.
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3.1.4 EGF induces dynamic translocation of EGFR to the Golgi
Furthermore, we examined the dynamic process of EGFR and Golgi
colocalization using a time-lapse confocal microscopy assay. We observed the
localization of enhanced green fluorescent protein (EGFP)-labeled EGFR on the cell
surface at time 0 of EGF stimulation after overnight serum starvation. After EGF
stimulation, we observed a gradual move of EGFR into the cytoplasm in which some
EGFR began to colocalize with Discosoma sp. red fluorescent protein (DsRed)syntaxin 6. In representative images from time-lapse confocal microscopy shown in
Figure 3-5, the green spots (EGFR) in inset 1 at the 6’20” time point moved closer to
the red spots (syntaxin 6; arrows) and some merged into yellow spots in insets 3-5 at
time points 7’00” to 7’40”.
Taken together, our data showed that EGF stimulation enhances the dynamic
translocation of EGFR to the Golgi apparatus.
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Figure 3-5

Figure 3-5: EGF induces the dynamic translocation of EGFR to the Golgi
apparatus. Fluorescence-labeled EGFP-EGFR (green) and DsRed-syntaxin 6 (red)
were transfected into HeLa cells. The movement of EGFR after EGF stimulation was
monitored using a live cell time-lapse confocal microscopy. Images were collected at
20-sec intervals and representative snapshot images at indicated time were shown.
Arrows indicate the representative colocalization of EGFR with syntaxin 6. Scale bar,
5 m.

3.2 Syntaxin 6 is required for the Golgi translocation of EGFR
3.2.1 EGF induces association of EGFR with syntaxin 6
Since syntaxin 6 is a key molecule to regulate membrane fusion between
endosomal vesicle and Golgi apparatus, we next asked whether syntaxin 6 associates
with EGFR to regulate the Golgi translocation of EGFR.
We first tested whether EGF can induce the colocalization of EGFR with
syntaxin 6 using confocal microscopy. As shown in Figure 3-6, EGFR colocalized
with syntaxin 6 upon EGF stimulation indicating the association between EGFR with
syntaxin 6 in response to EGF stimulation.
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Figure 3-6

Figure 3-6: EGF induces the colocalization of EGFR with the Golgi marker,
syntaxin 6. HeLa cells were transfected with pDsRed-Syn6 expression plasmid.
Cells were exposed to serum-free media overnight following treatment with EGF (50
ng/ml) for 20 min. The colocalization of EGFR with syntaxin 6 was examined with
confocal microscopy. All nuclei of cells were confirmed by DAPI staining. Green,
red, and blue channels: EGFR, Syn6, and nuclei, respectively. The boxed areas are
shown in detail in insets. Insets 2-1 and 2-2 are representative images showing the
colocalization of EGFR with syntaxin 6. Scale bars: 10 m.

We then examined whether EGFR interacts with syntaxin 6 using
immunoprecipitation (IP) assay. Our data showed EGFR was coimmunoprecipitated
with syntaxin 6 as examined with IP using anti-syntaxin 6 antibody followed by
immunoblotting (IB) using anti-EGFR antibody (Figure 3-7, left panel). This
interaction was confirmed with reciprocal IP using anti-EGFR antibody followed by
IB using anti-syntaxin 6 antibody (Figure 3-7, right panel). Taken together, our
results suggested that syntaxin 6 might have a role in Golgi transport of EGFR.
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Figure 3-7

Figure 3-7: EGF induces the association between EGFR and syntaxin 6. HeLa
cells were serum-starved overnight and stimulated with EGF (50 ng/ml) for 20 min.
Cell lysates were immunoprecipitated with the indicated antibodies and then
subjected to immunoblot (IB) analysis as indicated.

3.2.2 Downregulation of syntaxin 6 reduces the localization of EGFR at the Golgi
apparatus
To explore the function of syntaxin 6 in regulating the Golgi translocation of
EGFR, we used two small interfering RNAs (siRNAs) to knockdown the expression
of syntaxin 6 and examined its effect on the Golgi translocation of EGFR. As shown
in Figure 3-8 and Figure 3-9, knockdown of syntaxin 6 decreased the protein level of
EGFR in the Golgi-enriched fraction and EGF-induced colocalization of EGFR with
the Golgi marker, GalNac T2. When we used a dominant negative mutant of syntaxin
6, coiled-coil domain (CCD) (Kabayama et al., 2008), to inhibit the function of
syntaxin 6, we observed similar results, in which the EGF-induced colocalization of
EGFR with GalNac T2 was blocked (Figure 3-10). Quantitative results are shown in
the lower panels of Figures 3-9 and Figure 3-10. These results indicate that syntaxin 6
is required for the Golgi translocation of EGFR and imply that membrane fusion at
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the Golgi apparatus is involved in the transport of EGFR from cell surface to the
Golgi apparatus.

Figure 3-8

Figure 3-8: Knockdown of syntaxin 6 reduced EGFR protein level in the Golgi
enriched fraction. HeLa Cells were transfected with siRNA of syntaxin 6 or control
siRNA for 72 hr. After that, cells were serum starved overnight and then treated with
EGF (50 ng/ml) for 20 min. The EGFR level in the Golgi-enriched fraction (fraction
9) was analyzed using immunoblotting.
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Figure 3-9

Figure 3-9: Knockdown of syntaxin 6 expression reduces the colocalization of
EGFR with the Golgi marker GalNac T2. HeLa Cells were transfected with siRNA
of syntaxin 6 or control siRNA for 24 hr, and then transfected with GalNac T2
expression plasmid for 48 hr. After that, cells were serum starved overnight and then
treated with EGF (50 ng/ml) for 20 min. Then the colocalization of EGFR with
GalNac T2 was examined with confocal microscopy assay. All nuclei were confirmed
by DAPI staining. Green, red, and blue channels: EGFR, GalNac T2, and nuclei,
respectively. Scale bars: 20 m. The boxed areas are shown in detail in the insets.
Quantitative results are shown in the lower panel.
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Figure 3-10

Figure 3-10: Dominant negative mutation (CCD) of syntaxin 6 decreases the
colocalization of EGFR with the Golgi marker GalNac T2. Cells were transfected
with CCD domain of syntaxin 6 or control vector. After 48 hr transfection, cells were
serum starved overnight and then treated with EGF (50 ng/ml) for 20 min. Then the
colocalization of EGFR with GalNac T2 was examined with confocal microscopy.
All nuclei were confirmed by DAPI staining. Green, red, and blue channels: EGFR,
GalNac T2, and nuclei, respectively. Scale bars: 20 m. The boxed areas are shown
in detail in the insets. Quantitative results are shown in the lower panel.

3.3 Syntaxin 6 is required for nuclear translocation of EGFR
3.3.1 Depletion of syntaxin 6 by siRNAs decreases nuclear translocation of
EGFR
COPI-regulated retrograde transport from the Golgi apparatus to the ER has
been reported to mediate the nuclear translocation of EGFR (Wang et al., 2010a). Our
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results indicated that syntaxin 6-, microtubule-, and dynein-mediated intracellular
trafficking is required for EGF-induced Golgi translocation of EGFR. Therefore, we
asked whether syntaxin 6 is required for the downstream trafficking pathway of
EGFR to the nucleus.
We knocked down expression of syntaxin 6 by siRNAs and analyzed EGFR
expression in nuclear fractions. As shown in Figure 3-11, upon EGF stimulation,
EGFR was detected in the nuclear fraction of cells with syntaxin 6 expression.
However, when syntaxin 6 expression was knocked down, the level of nEGFR
significantly decreased. Consistently, confocal microscopy analysis showed EGFinduced localization of EGFR in the nucleus (Figures 3-12, insets 1 and 2; green
signal of EGFR merged with the blue signal of nucleus) was reduced in cells with
knockdown of syntaxin 6 (cells that do not have red color surrounding the nucleus)
compared to cells with syntaxin expression (Figure 3-12, insets 3 and 4; cells in red
color surrounding the nucleus). We quantitated the percentage of nEGFR-positive
cells in 100 cells under different conditions (lower panel of Figure 3-12) and found
the number of nEGFR-positive cells decreased as the results of syntaxin 6 knockdown.
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Figure 3-11

Figure 3-11: Knockdown of syntaxin 6 expression reduces nuclear EGFR level.
Cells were transfected with siRNAs of syntaxin 6 or control siRNA. Cells were
maintained in serum free media overnight and then treated with EGF (50 ng/ml) for
30 min. Non-nuclear and nuclear fractions were separated using cellular fractionation
and then subjected to immunoblot analysis using the indicated antibodies.
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Figure 3-12

Figure 3-12: Knockdown of syntaxin 6 expression blocks nuclear translocation
of EGFR. HeLa cells were transfected with siRNA of syntaxin 6 or a control siRNA.
Cells were maintained in serum-free media overnight and then treated with EGF (50
ng/ml) for 30 min. The colocalization of EGFR with syntaxin 6 was examined with
confocal microscopy. All nuclei were confirmed by DAPI staining. Green channel,
EGFR; red channel, syntaxin 6; blue channel, nuclei. The details of cells indicated by
arrows were shown in insets. Quantitation of positive cells with nEGFR is shown in
the lower panel. Scale bars, 20 m.

3.3.2 Dominant negative mutation of syntaxin 6 reduces nuclear translocation of
EGFR
Similarly, when a dominant negative mutant of syntaxin 6, coiled-coil domain
(CCD) (Kabayama et al., 2008), was used to inhibit the function of syntaxin 6, the
protein level of nEGFR (Figure 3-13) and the localization of EGFR in the nucleus
(Figure 3-14, insets 2 and 4; green signal of EGFR merged with the blue signal of
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nucleus) were decreased. Thus, we concluded that syntaxin 6-regulated Golgi
translocation of EGFR is critical for EGF-induced nuclear translocation of EGFR.
In summary, reduced nuclear translocation of EGFR by knockdown of
syntaxin 6 and inhibition of its function using CCD domain suggested that syntaxin 6
is required for the nuclear translocation of EGFR.

Figure 3-13

Figure 3-13: The CCD of syntaxin 6 decreases nuclear EGFR expression. HeLa
cells were transfected with a control vector or syntaxin 6 CCD. The cells were
maintained in serum-free media overnight and then stimulated with EGF (50 ng/ml)
for 30 min. Nuclear and nonnuclear fractions were subjected to immunoblot analysis
with the indicated antibodies.
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Figure 3-14

Figure 3-14: CCD domain decreases the nuclear translocation of EGFR. HeLa
cells were transfected with a control vector or syntaxin CCD. The cells were
maintained in serum-free media overnight and then stimulated with EGF (50 ng/ml)
for 30 min. The colocalization of EGFR with CCD domain of syntaxin 6 was
examined with confocal microscopy. All nuclei were confirmed by DAPI staining.
Green channel, EGFR; red channel, CCD. The boxed areas are shown in detail in
insets. Scale bars, 20 μm.

3.4 Syntaxin 6 is required for the transcriptional activity of nuclear EGFR
3.4.1 Downregulation of syntaxin 6 using siRNAs reduces DNA binding ability of
nuclear EGFR to the promoter of cyclin D1
EGFR has been reported to associate with cyclin D1 promoter to activate its
transcription in the nucleus (Huo et al., 2010; Lin et al., 2001). If syntaxin 6 is

53

important for the Golgi translocation and the downstream nuclear translocation of
EGFR, the inhibition of syntaxin 6 should affect the function of nuclear EGFR.
To confirm that syntaxin 6 is required for the function of nuclear EGFR, we
evaluated the effect of knockdown of syntaxin 6 on the DNA binding ability of
nuclear EGFR to the promoter of cyclin D1. As shown in Figure 3-15, when syntaxin
6 was knocked down by siRNAs, the DNA binding ability of nuclear EGFR was
decreased as indicated by ChIP assay.

Figure 3-15

Figure 3-15: Knockdown of syntaxin 6 reduces the binding of EGFR to the
promoter of cyclin D1. Cells were transfected with siRNAs of syntaxin 6. After 72
hr transfection, cells were serum starved overnight then stimulated with EGF for
30min. cells were then performed with chromatin-IP assay. For IgG control, lysate of
cells without EGF stimulation was used. Lower panel: Input of upper panel.

3.4.2 Downregulation of syntaxin 6 using siRNAs decreases EGF-induced mRNA
level of cyclin D1
To further confirm that syntaxin 6 regulated Golgi translocation of EGFR is
important for the function of nEGFR, we performed Luciferase assay using the
reporter plasmids containing cyclin D1 promoter. As shown in Figure 3-16,
knockdown of syntaxin 6 decreased EGF induced luciferase activity which indicated
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that knockdown of syntaxin 6 decreased the binding of nEGFR to the cyclin D1
promoter. Consistently, quantitative RT-PCR showed that when syntaxin 6 was
knocked down, the EGF-induced mRNA level of cyclin D1 was lower than that in
cells with control siRNA upon EGF stimulation (Figure 3-17).

Figure 3-16

Figure 3-16: Knockdown of syntaxin 6 inhibits EGF-induced luciferase activity
of cyclin D1 promoter. HeLa cells transfected with control siRNA or siRNAs of
syntaxin 6 were transfected with reporter plasmids containing cyclin D1 promoter.
Then after 24 hr transfection, cells were serum starved overnight and treated with
EGF for indicated time. Total cell lysates were used for luciferase assay. Error bars
were derived from three independent experiments.
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Figure 3-17

Figure 3-17: Depletion of syntaxin 6 reduces mRNA expression of cyclin D1.
Cells were transfected with shRNA of syntaxin 6. After 72 hr transfection, cells were
serum starved overnight and then stimulated with EGF for indicated time.
Quantitative-PCR was used to analyze the mRNA level of cyclin D1. Error bars were
derived from three independent experiments.

Taken together, these results indicated that syntaxin 6 is critical for the
transcriptional activity of nEGFR and provided another layer of support for the
importance of syntaxin 6-mediated Golgi translocation in EGF-induced nuclear
translocation of EGFR.
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Chapter Four
Microtubule cytoskeleton regulates the Golgi
and nuclear translocation of EGFR
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4.1 Microtubules and dynein are required for EGFR translocation from the cell
surface to the Golgi and nucleus
4.1.1 Disruption of microtubules blocks the Golgi translocation of EGFR
Since microtubules and their motor proteins play critical roles in intracellular
trafficking of most organelles in cytoplasm including the Golgi apparatus (Caviston
and Holzbaur, 2006; Rogers and Gelfand, 2000; Soldati and Schliwa, 2006), we asked
whether EGFR-embedded endocytic vesicles move along the microtubules to reach
the Golgi apparatus.
To this end, we first tested whether trafficking of EGFR from the cell surface
to the Golgi apparatus requires microtubule formation. Indeed, treatment of cells with
microtubule inhibitors, nocodazole and paclitaxel, decreased EGF-induced EGFR
translocation to the Golgi apparatus as is evident from the decreased EGFR protein
level in Golgi-enriched fraction 9 (Figure 4-1, lanes 3 and 4 vs. lane 2). This was
further supported by confocal microscopy analysis. As shown in Figure 4-2, EGFinduced colocalization of EGFR with the Golgi apparatus, which is indicated by the
merged EGFR (green) and GalNac T2 (red) signals shown in yellow (Figure 4-2,
inset 2 vs. inset 1), was disrupted in cells pretreated with microtubule inhibitors,
nocodazole and paclitaxel (Figure 4-2, insets 3 and 4 vs. inset 2; quantitative results
were shown in the lower panel of Figure 4-2). Moreover, using time-lapse confocal
microscope assay, we observed the blocking of dynamic trafficking of EGFR to the
Golgi apparatus by microtubule inhibitor nocodazole (Movie 2 vs. 3).
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Figure 4-1

Figure 4-1: Inhibitors of microtubules and dynein decrease EGFR protein level
in the Golgi-enriched fraction. Serum-starved HeLa cells were treated with
microtubules inhibitors (nocodazole or paclitaxel) or dynein inhibitors (EHNA and
vanadate) and then stimulated with EGF (50ng/ml). The expression of EGFR in
Golgi-enriched fraction was analyzed with immunoblotting. Noc, nocodazole; PT,
paclitaxel; Van, vanadate; Vti1b, marker of Golgi.
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Figure 4-2

Figure 4-2: Inhibitors of microtubules and dynein block the colocalization of
EGFR with the Golgi marker GalNacT2. HeLa cells were transfected with GalNac
T2 expression plasmid. After 24 hr transfection, cells were treated with microtubules
inhibitors (nocodazole or paclitaxel) or dynein inhibitors (EHNA and vanadate). Cells
were then serum-starved overnight and stimulated with EGF (50ng/ml). The
colocalization of EGFR with GalNac T2 was examined with confocal microscopy.
All nuclei were confirmed by DAPI staining. Green, red, and blue channels: EGFR,
GalNac T2, and nuclei, respectively. Scale bars, 20 m. The boxed areas are shown in
detail in the insets. Representative colocalization of EGFR with GalNac T2 is shown
in inset 2-1. Quantitated colocalization of EGFR and Golgi marker is shown in the
lower panel. Noc., nocodazole; PT., paclitaxel; Van., vanadate.
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4.1.2 CDK1 decreases Golgi translocation of EGFR
CDK1 has been reported to depolymerize microtubules through direct
phosphorylation of β-tubulin or indirect phosphorylation of microtubule associated
protein. To further confirm the function and importance of microtubules in Golgi
translocation of EGFR, we disrupted microtubules’ formation by overexpression of
CDK1 and its activator, cyclin B, to depolymerize microtubules through a natural
occurring process. We found that overexpression of CDK1 decreased the
colocalization of EGFR with the Golgi marker, GalNac T2, in response to the EGF
stimulation (Figure 4-3).

Figure 4-3

Figure 4-3: CDK1 decreases the colocalization of EGFR with the Golgi marker
GalNac T2. HeLa cells were transfected with GalNac T2 expression plasmid. After
24 hr transfection, cells were transfected with plasmids coding CDK1 and cyclin B.
Cells were then serum-starved overnight and stimulated with EGF (50ng/ml). The
colocalization of EGFR with GalNac T2 was examined with confocal microscopy.
All nuclei were confirmed by DAPI staining. Green, red, magenta, and blue channels:
EGFR, GalNac T2, CDK1, and nuclei, respectively. The boxed areas are shown in
detail in the insets. Quantitated colocalization of EGFR and Golgi marker is shown in
the right panel.
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Taken together, reduced Golgi translocation of EGFR by depletion of
microtubules with inhibitors and depolymerization of microtubules by CDK1
suggested that microtubule formation is required for EGF-induced EGFR trafficking
from the cell surface to the Golgi apparatus.

4.1.3 Dynein is required for the Golgi translocation of EGFR
Microtubule-dependent nucleated movement requires dynein, which contains
ATPase functional domain to utilize ATP to generate energy for movement.
Therefore, we asked whether dynein also plays a role in EGF-induced EGFR
trafficking to the Golgi apparatus. When cells were treated with dynein inhibitors,
EHNA

(erythro-9-[2-hydroxy-3-nonyl]-adenine)

and

vanadate,

EGF-induced

translocation of EGFR to the Golgi was attenuated as indicated by decreased EGFR
protein level in the Golgi-enriched fraction (Figure 4-1, lanes 5 and 6 vs. lane 2) as
well as colocalization of EGFR with the Golgi marker GalNac T2 (Figure 4-2, insets
5 and 6 vs. inset 2).
In addition, we knocked down the expression of dynein by short hairpin
RNAs (shRNAs) and found that depletion of dynein decreased EGF-induced EGFR
protein level on the Golgi-enriched fraction (Figure 4-4).
Therefore, reduced Golgi translocation of EGFR by inhibition of dynein with
inhibitors and depletion of dynein with shRNAs suggested that dynein is required for
the translocation of EGFR from the cell surface to the Golgi.
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Figure 4-4

Figure 4-4: Knockdown of dynein expression decreases EGFR protein level in
Golgi-enriched fraction. Serum-starved HeLa cells were transfected with dynein
shRNAs. After 72 hr transfection, cells were serum starved overnight and then
stimulated with EGF (50ng/ml). The Golgi-enriched fraction was purified and
subjected to immunoblot analysis with indicated antibodies.

4.1.4 Inhibitors of microtubules block the colocalization of EGFR with syntaxin6
Syntaxin 6 is a key molecule to regulate membrane fusion between endosomal
vesicle and Golgi apparatus. Our results have demonstrated that EGFR associates
with syntaxin 6 and syntaxin 6 is required for the Golgi translocation of EGFR
(Chapter 3). We further asked whether microtubules also play a role in the association
of EGFR with syntaxin 6. Using time-lapse confocal microscope assay, we observed
the colocalization of EGFR with syntaxin 6 occurred at about 20 min upon EGF
treatment (Figure 4-5 and Movies 2 vs. 3). However, when we pre-treated cells with
nocodazole to disrupt microtubules, the colocalization of EGFR with syntaxin 6 was
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blocked (Figure 4-5, lower panel) suggesting that microtubules play an important role
in the association of EGFR with syntaxin 6.
In summary, our data showed that functional microtubules and dynein are
critical for the translocation of EGFR from the cell surface to the Golgi apparatus and
suggested that EGFR likely travels along the microtubules to reach Golgi and
interacts with syntaxin 6, which then facilitates membrane fusion between the Golgi
and the endocytic vesicle that carries EGFR.

Figure 4-5

Figure 4-5: Colocalization of EGFR with syntaxin 6 is blocked by microtubules
inhibitor nocodazole. Fluorescence-labeled EGFP-EGFR (green) and DsRedsyntaxin 6 (red) expression plasmids were transfected into HeLa cells. The movement
of EGFR after EGF stimulation was monitored using a live cell time-lapse confocal
microscopy. Images were collected at 30-sec intervals and representative snapshot
images at indicated time were shown. Arrows indicate the representative
colocalization of EGFR with syntaxin 6. Scale bar, 5 m. Noc, nocodazole.
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4.2 EGF induces EGFR/microtubule and EGFR/dynein association
Our results demonstrated the Golgi translocation of EGFR upon EGF stimulation
(Chapter Three). Microtubules and their motor protein dynein are required for this
process. In this Chapter, we explored how EGF induces the Golgi translocation of
EGFR via microtubules and dynein by a combination of different approach.

4.2.1 EGF induces association of EGFR with microtubules
We

tested

whether

EGFR

associates

with

microtubules

using

immunoprecipitation (IP) assay. As shown in Figure 4-6 (left panel), upon EGF
stimulation, coimmunoprecipitation of EGFR with tubulin was significantly increased
as examined with IP using anti-α-tubulin antibody followed by immunoblotting (IB)
using anti-EGFR antibody. This association was confirmed with reciprocal IP using
anti-EGFR antibody followed by IB using anti-α-tubulin antibody (Figure 4-6, right
panel).

Figure 4-6

Figure 4-6: EGF induces association of EGFR with -tubulin. HeLa cells were
serum-starved overnight and stimulated with EGF (50 ng/ml) for 20 min. Cell lysates
were immunoprecipitated with the indicated antibodies and then subjected to
immunoblot (IB) analysis as indicated
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4.2.2 EGF induces the colocalization of EGFR with microtubules
We next examined whether EGFR travels along the microtubules using
confocal microscopy analysis. As shown in Figure 4-7, EGFR localized on the cell
surface at 0 min of EGF stimulation. Then EGFR gradually transported into
cytoplasm when treated with EGF for 5 minutes and then accumulated around the
nucleus. Meanwhile, the green signal of EGFR on the cell surface merged with the
red signal of microtubules in the cytoplasm and produced yellow spots indicating the
colocalization of EGFR with microtubules.
The colocalization of EGFR with microtubules was further supported by
immunoelectron microscopy (Immuno-EM) analysis. As shown in Figure 4-8,
without EGF stimulation, EGFR was detected on the cell surface (inset 3); however,
upon addition of EGF, EGFR (black spots in insets 1 and 2) localized around
microtubules (triangles in insets 1 and 2).
Therefore, both confocal microscopy and Immuno-EM analyses demonstrated
that EGFR transport along microtubules upon EGF stimulation.
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Figure 4-7

Figure 4-7: EGF induces the colocalization of EGFR with microtubules. HeLa
cells maintained in serum-free media overnight were treated with EGF (20 ng/ml) for
different time. EGFR and microtubules were labeled with primary antibodies and
fluorescence secondary antibodies. The colocalization of EGFR with tubulin was
examined with confocal microscopy. All nuclei of cells were confirmed by DAPI
staining. Green, red, and blue channels represent EGFR, tubulin, and nuclei,
respectively. The boxed areas are shown in detail in insets. Scale bars, 20μm.

Figure 4-8

Figure 4-8: EGF induces localization of EGFR near microtubules. HeLa cells
were treated with or without EGF for 30 min and subjected to immuno-EM as
described in methods. MT, microtubules. Scale bars, 200 nm. Arrows indicate EGFR
and triangles indicate microtubules.
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4.2.3 EGF enhances the FRET efficiency from EGFR to microtubules
To further confirm that EGF induces EGFR to travel along the microtubules,
we studied the association of EGFR with microtubules upon EGF stimulation using
fluorescence resonance energy transfer (FRET), in which EGFP fused-EGFR served
as a donor and Alexa Flour 555 stained -tubulin served as an acceptor. The collected
raw data were calculated as described in Chapter two and the Fc image was generated
using the Youvan method (Douglas C. Youvan and William J. Coleman, 1997) and
the Zeiss FRET software program (Carl Zeiss, Thornwood, NY). As shown in Figure
4-9, we detected FRET from the acceptor (Fc Image; arrows) only in cells expressing
EGFR (Donor-EGFR) (compare images 1, 2 and 3 without EGF stimulation or
compare images 4, 5 and 6 with EGF stimulation). However, upon EGF stimulation,
FRET efficiency from the acceptor (microtubules) excited by the donor (EGFR) was
increased as the microtubule-like image (image 3 vs. 6). Quantitation of the FRET
efficiency is shown in the right panel (Figure 4-9). These results indicated that EGF
induced the localization of EGFR around microtubules and further confirmed that
EGFR travels along microtubules upon EGF stimulation.
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Figure 4-9

Figure 4-9: EGF enhances the FRET efficiency of microtubules from EGFR.
HeLa cells were transfected with pEGFP-EGFR (donor; green) alone or labeled with
a primary anti--tubulin antibody and Alexa Fluor 555 (acceptor; red) antibody alone.
A third condition was a combination of EGFP-EGFR and Alexa Fluor 555 with tubulin. A Fc image was obtained using the Zeiss FRET software program. Scale bars,
20 m. Quantitation of the FRET efficiency is shown in the right panel.
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4.2.4 EGF-induced perinuclear accumulation of EGFR requires the formation of
microtubules
IP, confocal microscopy, EM, and FRET analyses demonstrated that EGFR
transport along microtubules upon EGF stimulation. Finally, co-expressed EGFPEGFR and mRFP-tubulin were used to visualize the movement of EGFR in cells
using live cell imaging system. Under EGF stimulation, most EGFR moved forward
and back in the certain area in parallel to microtubule. This movement was disrupted
by microtubule inhibitor nocodazole (Figure 4-10). The amount of EGFR spots in the
perinuclear area at 15 and 30 minutes after EGF treatment was also decreased by
nocodazole (the lower panel of Figure 4-10) treatment. Although the movement of
single endocytic EGFR from cell surface to the nucleus along microtubule was not
observed, our data showed that the travel of EGFR from cell surface to the
perinuclear area requires the formation of microtubules.

4.2.5 Nocodazole reduces the ability of EGFR to move parallel to microtubule
Using Zeiss AxioVision tracking application, we tracked the movement of
more than 20 spots of EGFR. In Figure 4-11, we measured the maximum distance of
movement of each spot. Y-axis stands for the movement parallel to microtubules and
X-axis stands for the movement vertical to microtubules. Compared with EGF
treatment, nocodazole treatment significantly reduced the EGF-induced movement of
EGFR parallel to microtubules.
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Figure 4-10

Figure 4-10: EGF induced perinuclear accumulation of EGFR requires the
formation of microtubule. HeLa cells transfected with EGFP-EGFR and mRFP-αtubulin were maintained in serum-free media overnight. EGF stimulated cells with or
without nocodazole pre-treatment were subjected to time-lapse confocal microscopy .
Images at 15 and 30 min under each condition were used to quantify particles in the
perinuclear region. Noc, nocodazole.
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Figure 4-11

Figure 4-11: Nocodazole reduces the ability of EGFR to move parallel to
microtubule. HeLa cells were transfected with EGFP-EGFR and mRFP-tubule. After
collection of data using time-lapse confocal microscopy of living cells pretreated with
or without nocodazole plus EGF stimulation, EGF induced particles were tracked by
the AxioVision Tracking program. Spots in the plot indicated maximum movement of
these particles in two directions, parallel to microtubule or vertical to microtubule.
Blue spots indicated the particles under EGF stimulation and pink spots indicated the
particles under pretreatment of Nocodazole plus EGF stimulation.

4.2.6 EGF induces association of EGFR with dynein
Dynein is a major motor proteins utilized for the trafficking of cargo along the
microtubules. After demonstrating the movement of EGFR along the microtubules by
a combination of different approach, we asked whether dynein is involved in the
movement of EGFR. We first examined the association of EGFR with dynein by IP
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(Figure 4-12) and confocal microscopy (Figure 4-13) analyses. Both approaches
showed the association of EGFR with dynein upon EGF stimulation.

Figure 4-12

Figure 4-12: EGF induces association of EGFR with dynein. Serum-starved HeLa
cells were stimulated with EGF (50ng/ml) for 20 min. Cell lysates were
immunoprecipitated with the indicated antibodies and subjected to immunoblot (IB)
analysis as indicated.

Figure 4-13

Figure 4-13: EGF induces the colocalization of EGFR with dynein. HeLa cells
maintained in serum-free media overnight were treated with EGF (20 ng/ml). EGFR
and dynein were labeled with primary antibodies and fluorescence secondary
antibodies. The colocalization of EGFR with dynein was examined with confocal
microscopy. All nuclei of cells were confirmed by DAPI staining. Green, red, and
blue channels represent EGFR, dynein, and nuclei, respectively. The boxed areas are
shown in detail in insets. Scale bars, 20μm. Ctrl, control.
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4.2.7 Knockdown of dynein expression decreases association of EGFR with
tubulin
We then asked whether dynein is required for the association of EGFR with
tubulin. To that end, we used shRNAs targeting dynein to knock down dynein
expression and found that in the absence of dynein, EGFR no longer interacted with
-tubulin (Figure 4-14) indicating that dynein is required for microtubule-dependent
movement of EGFR.
In summary, our results indicated that EGF induces trafficking of EGFR along
the microtubules. The requirement of dynein for EGFR/-tubulin interaction
suggested that dynein may link EGFR to microtubules and facilitate microtubuledependent movement as the power provider for intracellular trafficking of EGFR.
These results resemble the previous studies in which transport of vesicles containing
an N-methyl-D-aspartate or γ-aminobutyric acid receptor along microtubules were
shown to be regulated by motor proteins or other co-regulators (Heisler et al., 2011;
Setou et al., 2000). Thus, it is conceivable that analogous to the previous model, the
endocytic vesicle containing EGFR interacts with dynein and tubulin and travels
along the microtubules (the right panel of Figure 4-14).
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Figure 4-14

Figure 4-14: Knockdown of dynein expression decreases the association of
EGFR with tubulin. Serum-starved HeLa cells with knockdown of dynein
expression were stimulated with EGF (50 ng/ml) for 20 min. Cell lysates were
immunoprecipitated with anti-α-tubulin antibody and subjected to immunoblot as
indicated. Right panel: model of EGFR transport along microtubules regulated by
dynein.

4.3 Microtubules mediate nuclear trafficking of EGFR
4.3.1 Disruption of microtubules using inhibitors blocks EGFR transport to the
nucleus
So far, our data indicated that EGF-induced endocytic EGFR travels to the
Golgi apparatus via microtubule-dependent movement and fuses with the Golgi
through syntaxin 6-mediated membrane fusion. Our group have demonstrated that
EGFR utilizes the COPI-regulated retrograde trafficking pathway (Wang et al., 2010a)
to move from the Golgi to ER, inner nuclear membrane, and then nuclear plasma
(Wang et al., 2010c). Based on these observations, we hypothesized that microtubuleand dynein-mediated movement of EGFR is also required for its downstream nuclear
translocation.
To test this possibility, we disrupted the formation of microtubules by
pretreating cells with microtubule inhibitors nocodazole or paclitaxel. Indeed, we
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found that EGF-induced nuclear level of EGFR (Figure 4-15) and colocalization of
EGFR with the nucleus (Figure 4-16) significantly decreased. Quantitation of the
confocal microscopy images is shown in the lower panel of Figure 4-16.

Figure 4-15

Figure 4-15: Microtubule inhibitors nocodazole and paclitaxel decrease nEGFR
expression. HeLa cells maintained in serum-free media overnight were treated with
nocodazole (Noc) or paclitaxel (PT) and then stimulated with EGF (50 ng/ml).
Nonnuclear and nuclear fractions were separated using cellular fractionation and then
subjected to immunoblot assay with indicated antibodies.
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Figure 4-16

Figure 4-16: Microtubule inhibitors block nuclear localization of EGFR. HeLa
cells were treated under the same conditions as in Figure 8-1. The localization of
EGFR in nucleus was examined with confocal microscopy. All nuclei were
confirmed by TO-PRO-3 staining. Green and red channels: EGFR and nuclei,
respectively. Quantitation of positive cells with nEGFR is shown in the lower panel.
Scale bars, 20 m. Noc, nocodazole; PT, paclitaxel.

4.3.2

Depolymerization

of

microtubules

by

CDK1

decreases

nuclear

translocation of EGFR
In addition to disrupt microtubule formation using chemical inhibitors, we
further used a naturally occurred process to depolymerize microtubules by
overexpressing CDK1 and its activator, cyclin B (Fourest-Lieuvin et al., 2006), and
tested the effects of depolymerized microtubules on nuclear translocation of EGFR.
As shown in Figure 4-17, compared with vector control, overexpression of CDK1
decreased the expression of EGFR in nucleus. Similar results were obtained using
confocal microscopy assay (Figure 4-18, inset 4 vs. inset 2). Quantitation of cells with
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nuclear EGFR in confocal microscopic images is shown in the lower panel of Figure
4-18.

Figure 4-17

Figure 4-17: CDK1 decreases EGFR expression in nucleus. HeLa cells were
transfected with a control vector or HA-CDK1 and cyclin B expression vectors
for 48 hr. After that, cells were maintained in serum-free media overnight and
then stimulated with EGF. Nuclear fraction was separated using cellular
fractionation. Nuclear fraction and total lysates were subjected to immunoblotting
with the indicated antibodies.
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Figure 4-18

Figure 4-18: CDK1 decreases EGF induced nuclear localization of EGFR. HeLa
cells were transfected with a control vector or HA-CDK1 and cyclin B expression
vectors for 48 hr. Cells were serum-starved overnight and then stimulated with EGF.
The colocalization of EGFR with tubulin was examined with confocal microscopy.
All nuclei were confirmed by DAPI staining. Green, red, and blue channels: EGFR,
tubulin, and nuclei, respectively. The boxed areas are shown in detail in insets.
Quantitation of positive cells with nEGFR is shown in the lower panel. Scale bars,
20μm.

4.3.3 Nocodazole reduces nuclear translocation of EGFR in live cells
Finally, we used time-lapse confocal microscopy to examine the effect of
microtubule inhibitor nocodazole on the dynamic nuclear translocation of EGFR.
EGFR was labeled with GFP and the inner nuclear membrane structure protein Lamin
B representing the boundary of nucleus was labeled with RFP. As shown in the upper
panel of Figure 4-19 (also in Movies S6 vs. S7), strong trafficking activity of EGFR
was observed as indicated by the movement of the green spots (EGFR) from cell
surface into cytosol. A few green spots representing nEGFR were detected in nucleus
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at the 23-min and 23.5-min after EGF stimulation (Figure 4-19, upper panels).
However, in the presence of nocodazole, without microtubules to serve as a
trafficking route, the endocytic EGFR stacked on the cell surface membrane, the
active trafficking of EGFR disappeared, and no EGFR signal could be detected in the
nucleus (Figure 4-19, lower panels). These results suggested that microtubules are
required for the nuclear translocation of EGFR and this is likely through the
regulation of Golgi translocation.
In summary, reduced nuclear translocation of EGFR by disrupting the
formation of microtubules and depolymerizing microtubules suggested that
microtubules coordinate the nuclear translocation of EGFR.

Figure 4-19

Figure 4-19: Microtubule inhibitor nocodazole blocks the dynamic nuclear
translocation of EGFR. Fluorescence-labeled EGFP-EGFR (green channel) and
RFP-lamin B (red channel) were transfected into HeLa cells. The movement of EGFR
after EGF stimulation was monitored using a live cell time-lapse confocal microscopy.
Images were obtained at 30-sec intervals and representative snapshot images at
indicated time points were shown. Scale bars, 10 m. Noc, nocodazole.
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4.4 Dynein coordinates the nuclear translocation of EGFR
4.4.1 Disruption dynein using inhibitors blocks the transport of EGFR to the
nucleus
We further asked whether dynein also regulates nuclear trafficking of EGFR.
To answer this question, we treated cells with dynein inhibitors, EHNA and vanadate,
and found that disruption of dynein ATPase activity decreased EGF-induced nuclear
translocation of EGFR according to the Western blot (Figure 4-20) and confocal
microscopy analyses (Figure 4-21). Quantitation of cells with nEGFR from the
confocal microscopy images is shown in the lower panel of Figure 4-21.

Figure 4-20

Figure 4-20: Inhibitors of dynein, EHNA and vanadate, decrease the protein
level of EGFR in the nucleus. Serum-starved HeLa cells were treated with EHNA or
vanadate and then stimulated with EGF (50 ng/ml). Nuclear and nonnuclear fractions
were separated using cellular fractionation and subjected to immunoblot analysis with
the indicated antibodies.
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Figure 4-21

Figure 4-21: Inhibitors of dynein, EHNA and vanadate, decrease the localization
of EGFR in the nucleus. HeLa cells were treated as described in Figure 9-1. The
localization of EGFR in nucleus was examined with confocal microscopy. All nuclei
were confirmed by TO-PRO-3 staining. Green and red channels: EGFR and nuclei,
respectively. Quantitation of positive cells with nEGFR is shown in the lower panel.
Scale bars, 20 μm. Van, vanadate.

4.4.2 Depletion of dynein by siRNAs reduces nuclear translocation of EGFR
To rule out the nonspecific effects of these inhibitors, we used siRNAs to
knock down the expression of dynein (Figure 4-22, lower panel) and examined the
effect of dynein knockdown on the nuclear translocation of EGFR. As shown in the
upper panel of Figure 4-22, depletion of dynein expression decreased EGF-induced
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nuclear translocation of EGFR. Confocal microscopy assay also showed that
knockdown of dynein expression decreased EGF-induced nuclear translocation of
EGFR (Figure 4-23). Thus, our data showed that microtubule motor protein dynein is
required for EGF-induced nuclear translocation of EGFR.

Figure 4-22

Figure 4-22: Knockdown of dynein decreases the expression of EGFR in nucleus.
HeLa cells were transfected with two dynein siRNAs for 48 hr, serum-starved
overnight, and then treated with 50 ng/ml EGF for 30 min. Non-nuclear and nuclear
fractions were separated using cellular fractionation and subjected to immunoblot
analysis with the indicated antibodies. Knockdown of dynein expression is analyzed
with immunoblot (lower panel).
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Figure 4-23

Figure 4-23: Knockdown of dynein inhibits nuclear location of EGFR. HeLa cells
were transfected with dynein siRNA and then treated as described in Figure 9-3. The
colocalization of EGFR with dynein was examined with confocal microscopy. All
nuclei were confirmed by DAPI staining. Green, red, and blue channels: EGFR,
dynein, and nuclei, respectively. Quantitation of positive cells with nEGFR is shown
in the lower panel. The boxed areas are shown in detail in the insets. Scale bars, 20
μm.

4.5 Disruption of microtubules and dynein reduces DNA binding ability of
nuclear EGFR to the promoter of cyclin D1
If microtubules and dynein are important for the Golgi translocation and the
downstream nuclear translocation of EGFR, the inhibition of microtubules and dynein
activities should affect the function of nEGFR.
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To test this hypothesis, we examined whether the binding of EGFR to the
promoter of targeted genes, such as cyclin D1, is affected by disruption of
microtubules and dynein by chromatin immunoprecipitation (ChIP) assay. As shown
in Figure 4-24, when microtubules and dynein were inhibited by chemical inhibitors,
EHNA and nocodazole, the EGF-induced binding of EGFR to the cyclin D1 promoter
was significantly decreased.
In summary, we identified a new trafficking pathway that regulates Golgi
translocation of EGFR after endocytosis via microtubule-dependent trafficking which
is required for the DNA binding ability of nuclear EGFR.

Figure 4-24

Figure 4-24: Inhibitors of microtubules and dynein decrease the binding of
EGFR to the promoter of cyclin D1. After overnight serum starvation, cells were
pretreated with indicated inhibitors for 30 min and then stimulated with EGF for 30
min followed by Chromatin-IP assay. For IgG control, lysate of cells without EGF
stimulation was used. Noc, nocodazole. Lower panel: Input of upper panel.
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Chapter Five
Syntaxin 6 and microtubule cytoskeleton
regulate the Golgi translocation of cholera toxin,
c-Met, and ErbB2
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5.1 Syntaxin 6 and microtubule cytoskeleton regulate the Golgi translocation of
cholera toxin
5.1.1 Disruption of microtubule and dynein decrease Golgi translocation of
cholera toxin
The data we presented above revealed a novel trafficking pathway regulating
the Golgi translocation of cellular protein, EGFR, via retrograde transport from the
cell surface. Foreign protein like cholera toxin has been reported to translocate to the
Golgi apparatus through the retrograde trafficking to activate its toxicity; however,
the

mechanism

is

not

well

understood.

Therefore,

we

asked

whether

microtubulin/dynein/syntaxin 6 axis identified in our study is also used by cholera
toxin.
We first confirmed the localization of cholera toxin at the Golgi apparatus
using confocal microscopy analysis (Figure 5-1, yellow spots in inset 2).
Quantitation of cells with cholera toxin localized at Golgi is shown in the lower panel
of Figure 5-1. When microtubules and dynein were disrupted with inhibitors, EHNA
and nocodazole, colocalization of cholera toxin with the marker of Golgi apparatus
was significantly decreased (Figure 5-1, insets 3 and 4).
We further isolated the Golgi-enriched fraction and examined the effects of
disruption of microtubules and dynein on the localization of cholera toxin at the Golgi
apparatus. As shown in Figure 5-2, the level of cholera toxin in Golgi-enriched
fraction decreased when cells were pretreated with inhibitors of microtubules and
dynein.
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Figure 5-1

Figure 5-1: Inhibitors of microtubules and dynein reduce accumulation of
cholera toxin at the Golgi apparatus. HeLa cells transfected with GalNac T2
expression plasmid for 48 hr were pretreated with control DMSO or indicated
inhibitors for 30 min and then treated with RFP fused cholera toxin for 1 hr. The
colocalization of cholera with GalNac T2 was examined with confocal microscopy.
All nuclei were confirmed by DAPI staining. Green, red, and blue channels: cholera
toxin (CT), GalNac T2, and nuclei, respectively. Scale bars, 20 m. Noc, nocodazole.
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Figure 5-2

Figure 5-2: Inhibitors of microtubules and dynein reduce cholera toxin at the
Golgi enriched fraction. HeLa cells transfected with GalNac T2 expression plasmid
for 48 hr were pretreated with control DMSO or indicated inhibitors for 30 min and
then treated with cholera toxin for 1 hr. The presence of cholera toxin at Golgi
enriched fraction was examined with Western blot assay. Noc, nocodazole.

5.1.2 Depletion of syntaxin 6 by siRNAs blocks Golgi translocation of cholera
toxin
Next we knocked down the expression of syntaxin 6 and examined its effect
on the Golgi trafficking of cholera toxin. As shown in Figure 5-3, cholera toxin
colocalized with the Golgi marker, GalNac T2, in cells transfected with control
siRNA (Figure 5-3, yellow color in inset 1). When syntaxin 6 was knocked down,
colocalization of cholera toxin with GalNac T2 was significantly reduced (Figure 5-3,
insets 2 and 3). Quantitation of cells with cholera toxin at the Golgi apparatus is
shown in the right panel of Figure 5-3. We also observed similar results when we
used the dominant negative mutant (CCD domain) of syntaxin 6 to inhibit the
function of syntaxin 6. Compared with vector control, the CCD domain of syntaxin 6
significantly decreased the colocalization of cholera toxin with GalNac T2 (Figure 54, insets 1 and 2), indicating that syntaxin 6 is required for the Golgi accumulation of
cholera toxin.
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Collectively, these results further demonstrated that not only do syntaxin 6
and microtubules regulate intracellular trafficking of EGFR to Golgi and contribute to
downstream nuclear transport but also mediate Golgi translocation of foreign
molecule such as the cholera toxin. This pathway which regulates the Golgi
translocation through microtubule-dependent movement and syntaxin 6-mediated
membrane fusion likely serves as a general model for intracellular trafficking of
cellular or foreign molecules.

Figure 5-3

Figure 5-3: Depletion of syntaxin 6 by siRNAs reduces the localization of cholera
toxin at the Golgi apparatus. HeLa cells were transfected with siRNAs of syntaxin
6 for 24 hr then transfected with GalNac T2 expression plasmid for 48 hr. Transfected
cells were then treated with RFP fused cholera toxin for 1 hr. The colocalization of
cholera toxin with GalNac T2 was examined with confocal microscopy. All nuclei
were confirmed by DAPI staining. Green, red, and blue channels: cholera toxin (CT),
GalNac T2, and nuclei, respectively. Scale bars, 20 m.
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Figure 5-4

Figure 5-4: Downregulation of syntaxin 6 by CCD domain reduces the
localization of cholera toxin at the Golgi apparatus. HeLa cells were cotransfected with CCD domain of syntaxin 6 and GalNac T2 expression plasmid for 48
hr. Transfected cells were then treated with RFP fused cholera toxin for 1 hr. The
colocalization of cholera toxin with GalNac T2 was examined with confocal
microscopy. All nuclei were confirmed by DAPI staining. Green, red, and blue
channels: cholera toxin (CT), GalNac T2, and nuclei, respectively. Scale bars, 20 m.

5.2 Depletion of syntaxin 6 and disruption of microtubule-dependent movement
decrease Golgi translocation of c-Met
C-Met has been reported to transport to the Golgi apparatus in response to
HGF stimulation. However its mechanism is not clear. Therefore, we tested whether
c-Met utilizes the same trafficking pathway identified in our study for its Golgi
translocation.
We first knocked down the expression of syntaxin 6 in HeLa cells using
siRNAs of syntaxin 6 and tested its effect on the localization of c-Met at the Golgi
apparatus. As shown in Figure 5-5, we detected the colocalization of c-Met with the
Golgi marker, GalNac T2, upon HGF stimulation. When syntaxin 6 expression was
knocked down by siRNA, the colocalization of c-Met with GalNac T2 was decreased
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which implied that syntaxin 6 regulated membrane fusion is involved in the Golgi
translocation of c-Met.
We then examined the function of microtubules and its motor protein dynein
during the Golgi translocation of c-Met. We disrupted the function of microtubules
and dynein with inhibitors, nocodazole and EHNA, and found this treatment reduced
the colocalization of c-Met with the Golgi apparatus upon HGF stimulation (Figure 56). These results indicated that microtubules and dynein are required for the Golgi
translocation of c-Met.

Figure 5-5

Figure 5-5: Knockdown of syntaxin 6 reduces the Golgi localization of c-Met.
Cells were transfected with siRNAs of syntaxin 6 or control siRNA. After 24 hr
transfection, HeLa cells were transfected with GalNac T2 expression plasmid for 24
hr. Cells were then serum-starved overnight and then treated with HGF (100 ng/ml)
for 60 min. The colocalization of c-Met with the Golgi marker GalNac T2 was
examined using confocal microscopy assay. All nuclei were confirmed by DAPI
staining. Green, red, and blue channels: EGFR, GalNac T2, and nuclei, respectively.
Scale bars, 20 m. The boxed areas are shown in detail in the insets.
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Figure 5-6

Figure 5-6: Inhibitors of microtubules and dynein block the colocalization of cMet with the Golgi apparatus. HeLa cells transfected with GalNac T2 were treated
with control DMSO or indicated inhibitors for 30 min. The colocalization of c-Met
with the Golgi marker GalNac T2 was examined using confocal microscopy assay.
All nuclei were confirmed by DAPI staining. Green, red, and blue channels: c-Met,
GalNac T2, and nuclei, respectively. Scale bars, 20 m. The boxed areas are shown in
detail in the insets.

5.3 Disruption of microtubule and dynein decreases nuclear translocation of
ErbB2
We also depleted dynein and syntaxin 6 with specific siRNAs and then
analyzed the nuclear translocation of ErbB2 using Western blotting. Similar to the
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results of EGFR, nuclear translocation of ErbB2 was decreased when microtubules
(Figure 5-7), dynein (Figures 5-7 and 5-8), and syntaxin 6 (Figure 5-9) were disrupted,
demonstrating that nuclear translocation of ErbB2 occurs through regulated
trafficking from the cell surface to the Golgi apparatus. This process is also mediated
by syntaxin 6, microtubules, and dynein.
In summary, trafficking of cell surface receptors, c-Met and ErbB2, utilize
similar pathway to transport either to the Golgi apparatus (c-Met) or the nucleus
(ErbB2).

PT
EHNA

Noc.

Van.

ErbB2 shorter exposure

Nuclear

Ctrl

Figure 5-7

ErbB2 longer exposure
Lamin B
Calregulin

Total

ErbB2
Actin

Figure 5-7: Inhibition of microtubules and dynein decreases nuclear
translocation of ErbB2. SKBr3 cells were treated with microtubule or dynein
inhibitors for 1 hr. Nuclear fraction was separated using cellular fractionation and
then subjected to immunoblotting with the indicated antibodies. Noc., nocodazole;
PT., paclitaxel; Van., vanadate.
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Figure 5-8: Knockdown of dynein decreases the nuclear translocation of
ErbB2. SKBr3 cells were transfected with dynein siRNAs or control siRNA.
Nuclear fractions were separated using cellular fractionation. The presence of
ErbB2 in nuclear fractions and total lysis were analyzed using immunobloting
assay with indicated antibodies. Lower panel: knockdown of dynein.

Figure 5-9

Figure 5-9: Knockdown of syntaxin 6 decreases the nuclear translocation of
ErbB2. SKBr3 cells were transfected with syntaxin 6 siRNAs or control siRNA.
Nuclear fractions were separated using cellular fractionation. The presence of
ErbB2 in nuclear fractions and total lysis were analyzed using immunobloting
assay with indicated antibodies. Lower panel: knockdown of syntaxin 6.
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Chapter Six
Summary, discussion, significance, and future
directions
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6.1 Summary
A schematic representation of EGFR trafficking to the Golgi and nucleus
proposed in our study was shown in Figure 6-1. This model is supported by the
results described here.

Figure 6-1: Study model.

First, we showed that EGF induced EGFR to transport into the Golgi
apparatus supported by the colocalization of EGFR with different Golgi markers
using confocal microscopy assay. This notion is further supported by biochemical
method in which the EGFR level in the Golgi-enriched fraction was enhanced by
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EGF stimulation. Inhibition of protein synthesis does not change the colocalization
pattern of EGFR with the Golgi marker upon EGF stimulation indicating that EGFR
on the Golgi induced by EGF comes from the cell surface. Most importantly, the
dynamic translocation of EGFR to the Golgi was observed by a living cell imaging
system.
Second, we found syntaxin 6, microtubules, and dynein are required for the
Golgi transport of EGFR. It is supported by the blocking of EGFR translocation from
cell surface into the Golgi apparatus due to downregulation of syntaxin 6 and
inhibition of microtubule and motor protein dynein. We also showed EGF induces the
association of EGFR with syntaxin 6, tubulin, and motor protein dynein. Our data
suggest that dynein may link EGFR to microtubules and facilitate microtubuledependent movement as the power provider for intracellular trafficking of EGFR.
Based on these results, we proposed that EGFR likely travels along the microtubules
to reach Golgi and interacts with syntaxin 6, which then facilitates membrane fusion
between the Golgi and the endocytic vesicle that carries EGFR.
Third, we demonstrated that syntaxin 6, microtubule, and dynein are required
for the nuclear trafficking of EGFR via mediation of trafficking from the cell surface
to the Golgi apparatus. This is supported by the decrease of EGFR nuclear
translocation due to downregulation of syntaxin 6 either by siRNAs knockdown or
dominant negative mutant of syntaxin 6 and disruption of microtubules and dynein by
inhibitors and siRNAs.
More importantly, we demonstrated that syntaxin 6 and microtubuledependent movement of EGFR are critical for the transcriptional activity of nEGFR.
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This is supported by the decreased association of nuclear EGFR with the promoter of
cyclin D1 and the decreased transcriptional activity of nEGFR due to knockdown of
syntaxin 6 and inhibition of microtubules and dynein. These results provide another
layer of support for the importance of microtubule- and syntaxin 6-mediated Golgi
translocation in EGF-induced nuclear translocation of EGFR.
In addition, we showed that syntaxin 6 and microtubules not only regulate
intracellular trafficking also mediate the Golgi translocation of foreign molecules,
such as the cholera toxin, and other cell surface molecules, such as c-Met, as well as
the nuclear translocation of ErbB2. This is supported by the decreased Golgi
translocation of cholera toxin and c-Met and nuclear translocation of ErbB2 by
syntaxin 6 knockdown and inhibition of microtubules and dynein.
In summary, this pathway which regulates the Golgi translocation through
microtubule-dependent movement and syntaxin 6-mediated membrane fusion likely
serves as a general model for intracellular trafficking of cellular or foreign molecules.

6.2 Discussion
Cellular distribution of cell surface receptors is considered to be more
complicated than degradation and recycling. After receptor-regulated endocytosis,
RTKs continue to activate downstream signals (Lemmon and Schlessinger, 2010;
Sadowski et al., 2009). Recent studies have reported that RTKs, such as EGFR,
FGFR1, and VEGFR1, transport to the Golgi, mitochondrial, and nucleus, (Demory et
al., 2009; Hitosugi et al., 2011; Mittar et al., 2009; Wang et al., 2010b), implying that
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cell surface receptors may have non-canonical function at different cellular
compartments.
Since the discovery of nuclear translocation of EGFR more than 20 years ago
(Kamio et al., 1990; Raper et al., 1987), many studies have identified important
biological functions of nuclear EGFR, including cell proliferation, DNA synthesis,
DNA repair, radiation response, and drug resistance (Dittmann et al., 2010; Huang et
al., 2011; Li et al., 2009; Li et al., 2010; Liccardi et al., 2011; Lo and Hung, 2006;
Wang and Hung, 2009). However, the field of nuclear RTKs has progressed slowly
partly due to a lack of clear trafficking mechanism of cell surface receptors to the
nucleus. Although the partial mechanism of nuclear translocation of EGFR has been
demonstrated, including endocytosis (Bryant et al., 2005; Giri et al., 2005; Lo et al.,
2006), nuclear localization signals (NLS), importin 1/1 (Giri et al., 2005; Hsu and
Hung, 2007; Lin et al., 2001; Lo et al., 2006; Offterdinger et al., 2002; Reilly and
Maher, 2001; Srinivasan et al., 2000), COPI-mediated retrograde trafficking from the
Golgi to the ER (Wang et al., 2010a), translocon, and Sec61-regulated release of
EGFR from the ER membrane (Liao and Carpenter, 2007; Wang et al., 2010c),
experimental data demonstrating the Golgi translocation of EGFR is still absent. Our
present findings fill the gap and indicate how EGFR is transported to the Golgi/ER
after endocytosis and then into the nucleus.
Our results suggest that SNARE protein, syntaxin 6, regulates EGFR
translocation to the Golgi and intracellular trafficking of EGFR is not a random
process. Rather, EGFR moves along MTs powered by the motor protein, dynein. In
addition, we also showed that cholera toxin uses similar trafficking pathway for its
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pathological function. Several unique observations led to these conclusions: 1)
Cellular protein like EGFR is transported to the Golgi in response to EGF stimulation
and this process requires syntaxin 6, indicating that membrane fusion may be a
critical trafficking event for the Golgi translocation. EGFR remains membrane-bound
during the Golgi trafficking. 2) MTs and dynein are both required for the
translocation of EGFR to the Golgi. MTs have been reported to function in
endosomal trafficking to the lysosome and membrane trafficking between the Golgi
and ER (Caviston and Holzbaur, 2006). Our study further shows that the intracellular
trafficking of cell surface receptors from endosome to the Golgi also requires MTs,
indicating that MTs may serve for most intracellular trafficking; and 3) MT and
dynein inhibitors blocked nuclear translocation of EGFR and decreased
transcriptional activity of nEGFR, indicating that the Golgi translocation of EGFR is
a critical trafficking step for downstream trafficking of EGFR, nuclear translocation.
Together with the previous studies (Liao and Carpenter, 2007; Wang et al., 2010a;
Wang et al., 2010c), our study reveals a model showing schematic representation of
the Golgi translocation of EGFR. EGFR, carried by endocytic vesicles along the MT
cytoskeleton, is transported to the Golgi by syntaxin 6-mediated membrane fusion. In
conjunction with the previous studies showing both transport of EGFR from the Golgi
to the ER via COPI-regulated retrograde trafficking and translocon Sec61-mediated
trafficking of EGFR released from ER or the inner nuclear membrane, our study
provides a clear mechanism outlining the Golgi and nuclear translocation of EGFR.
This newly identified mechanism not only contributes to nuclear translocation
of cell surface receptors but also reveals a potential trafficking route of foreign
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proteins like the cholera toxin. Protein toxins enter the cell through retrograde
trafficking pathway to the Golgi and ER and then released into the cytoplasm by
Sec61-regulated ER-associated degradation (ERAD). However, instead of being
degraded, they are activated to increase cAMP activation, which in turn causes the
dehydration of target cells. Although retrograde transport is partially involved, the
complete mechanism

is

unknown. The proposed mechanism

provides a

comprehensive trafficking pathway showing that MTs, dynein, and syntaxin 6
regulate the trafficking of cholera toxin into the Golgi and ER. Current treatment for
cholera is primarily oral rehydration salts. Although antibiotic can also be used to kill
the bacteria, it takes time for the effect to take place and is not effective in stopping
dehydration as the effect of the toxin lingers on even after all the bacteria are killed. If
the mechanism we have provided can be used to decrease the toxin activity in target
cells, disruption of Golgi trafficking of cholera toxin may be a potential treatment by
quickly reducing dehydration in target cells.

6.3 Significance
Combined with previous studies, our works provide a systemic model to
explain how cell surface receptors containing the transmembrane domain translocate
into the nucleus. Our study is unique and significant for the following reasons.
First, it provides a new concept that membrane fusion mediated by SNARE
protein may be involved in the nuclear translocation of RTKs. Previous studies of
nuclear transport of cell surface receptors focused on how these molecules are
released from membrane components (Massie and Mills, 2006). However, in our
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model, we opened another perspective to the mechanism of nuclear transport of RTKs
and even other cell surface receptors. By this general mechanism, these membrane
proteins are anchored on the membrane following retrograde trafficking pathway and
membrane flux to reach the nucleus. Our findings fill the gap of how the EGFR is
transported to the ER after endocytosis.
Second, it is the first time to reveal the correlation between cytoskeleton and
nuclear translocation of EGFR by demonstrating that microtubule cytoskeleton
provides a directional movement pathway for the nuclear translocation of EGFR.
Third, we showed that other cell surface receptor, such as ErbB2, also uses the
same mechanism to translocate into the nucleus (Figures 12-3, 12-4, and 12-5). It
suggests that the model proposed in our study is a general mechanism through which
RTKs and other cell surface receptors translocate from cell surface into the nucleus to
carry out their nuclear functions.
Finally, our study opens a new avenue to understand the trafficking
mechanism for not only EGFR but also other cell surface molecules which have
similar trafficking events. Since non-canonical trafficking of cell surface receptors are
usually correlates with tumorigenesis, understanding their trafficking mechanisms
may provide potential clinical implication for current therapy of cancer patients.

6.4 Future Directions
While the Golgi trafficking model depicted in our study is attractive, a few
questions still need to be further investigated. For example, it is not known whether
EGFRs have specific functions at the Golgi apparatus in addition to docking at the
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Golgi for further intracellular trafficking. It has been reported that other SNARE
proteins, e.g., vSNARE, may cooperate with syntaxin 6 to regulate membrane fusion
(Jahn and Scheller, 2006). For example, VAMP3 and VAMP4 have been reported to
cooperate with syntaxin 6 to regulate membrane fusion between vesicles and the
Golgi (Zeng et al., 2003; Zwilling et al., 2007). Therefore, it is worth investigating
whether vSNARE is required for the Golgi translocation of EGFR. Another group of
molecules, small GTPase Rabs, are involved in retrograde trafficking pathway
(Johannes and Popoff, 2008). It would also be interesting to investigate which Rab
protein regulates the transport of EGFR to the Golgi after endocytosis. It is
worthwhile to mention that EGF induces EGFR degradation through receptormediated endocytosis and endosomal trafficking to the lysosomes. How EGFR
bypasses this degradation pathway or whether different populations of EGFR have
different fates, for example either into lysosome or other cellular compartments such
as mitochondria (Boerner et al., 2004) or the nucleus, remains to be investigated.
More importantly, we will address whether blocking of nuclear trafficking of EGFR
affects the sensitivities of cancer cells to tyrosine kinase inhibitors or radiotherapy.

In summary, the following questions need to be addressed in our future work.

1. How is the different cellular compartment trafficking of EGFR decided upon EGF
stimulation? What molecules control the fate of intracellular trafficking of EGFR?
EGF induced the endosomal trafficking of EGFR for degradation in the lysosome
in order to terminate EGFR signal transduction (Waterman et al., 1998). However, in
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our study, we found that EGF also induced the Golgi and nuclear translocation. Thus
we will investigate the switch which controls the different trafficking events of EGFR
upon EGF stimulation.

2. What is the specific function of EGFR on the Golgi apparatus?
In our study, EGFR translocated into the Golgi and linked with the ER
translocation for the final destination of nuclear location. Intracellular trafficking of
proteins is usually related to some specific functions. For example, the lysosomal
trafficking of EGFR is for degradation (Yarden and Shilo, 2007). Nuclear trafficking
of EGFR is related to the transcriptional regulation, DNA repair, and DNA replication
(Wang et al., 2010b). Recent study showed that EGFR transport to the mitochondria
to regulate mitochondrial function through phosphorylation of COXII (Demory et al.,
2009)or is correlated with cell survival (Yue et al., 2008).
However, the functions of Golgi translocated EGFR and even other cell surface
proteins are not clear so far. When the Golgi translocation of transferin receptor was
observed 30 years ago, its function was proposed to repair the damaged glycolysation
of receptor (Snider and Rogers, 1985). However, there was no experimental evidence
to support this hypothesis. Recently some results showed that Golgi localized c-Met
is still active (Kermorgant and Parker, 2008) indicating that Golgi localized cellular
protein may have some specific functions and the Golgi apparatus is not just the place
for glycolysation of newly synthesized proteins. Using unbiased assay, Dr. Lynda
Chin’s team reported a critical function of one Golgi associated protein in
tumorigenesis (Scott and Chin, 2010). Their studies demonstrated that Golgi may not
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only be the place to modify proteins, but also has physiological and pathological
function through regulation of signaling cascades. Our data demonstrated that EGFinduced Golgi translocation of EGFR is a critical trafficking step for the nuclear
translocation of EGFR and contributes to the transcriptional activity of nuclear EGFR.
In our future work we will investigate whether Golgi-localized EGFR has other
specific functions.

3. What are the functions of other SNARE proteins paired with syntaxin 6 in
regulating the Golgi and nuclear translocation of EGFR?
Target SNARE usually pairs with vesicle SNARE and other two target SNAREs
to play a full function in membrane fusion (Johannes and Popoff, 2008). Thus the
syntaxin 6 as a target SNARE may work with other SNARE protein to regulate the
Golgi translocation of EGFR. The identification of other SNARE proteins may
provide fully understanding for the membrane fusion event which regulates the Golgi
translocation of EGFR.

4. Are there any other type of proteins regulating the Golgi and nuclear translocation
of EGFR? Which Rab protein plays a role during these traffickings?
It is known that other molecules including adaptor proteins, membrane coated
proteins, tethering factors, and docking factors are required for the retrograde
trafficking pathway (Johannes and Popoff, 2008). These proteins cooperate with each
other to mediate membrane fusion events. Further identifying other regulators
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required for the Golgi translocation of EGFR will provide more potential clinical
applications for diseases caused by nuclear translocation of EGFR.
5. What is the mechanism of ligand-independent nuclear trafficking of EGFR?
Our studies identified the intracellular trafficking pathway of EGFR upon EGF
stimulation from cell surface to the Golgi apparatus and demonstrated that this
pathway is critical for downstream nuclear transport and its transcriptional function.
However, as we know that nuclear localization of EGFR had been detected under
different stress exposure including oxygen stress, DNA damage reagents, and
radiation treatment (Dittmann et al., 2010; Li et al., 2010). Whether intracellular
trafficking pathway identified in our study is also used for ligand-independent
trafficking of EGFR is an interesting question. We will also investigate whether there
are other mechanisms to regulate ligand-independent nuclear transport of EGFR.

6. Whether blocking nuclear trafficking of EGFR can increase the sensitivity of
cancer cells to TKIs, Cetuximab, or radiotherapy?
Recent study demonstrated that nuclear EGFR contributes to the resistance of
cancer cells to tyrosine kinase inhibitor through turning on the expression of BCRP
gene (Huang et al., 2011), which may play a major role in multi-drug resistance. In
addition, it has been reported that acquired-resistance of lung cancer cell lines to
Cetuximab is caused by the nuclear EGFR (Brand et al., 2011). Furthermore,
radiation treatment is reported to be another stress to induce nuclear translocation of
EGFR to enhancing DNA repair (Dittmann et al., 2010). These results suggest that
blocking nuclear translocation of EGFR may result in synergistic effect when
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combined with chemotherapies or radiation therapies. Therefore, we will investigate
the effects of blocking EGFR nuclear trafficking on the sensitivities of cancer cells to
TKIs, Cetuximab, or radiotherapy in our future work.
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